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1 Abstract  
 
Positron emission tomography (PET) is increasingly being used by the pharmaceutical industry in 
drug development. Drugs are designed to bind to a specific target, which is usually a membrane 
embedded receptor or an enzyme. PET is used to establish the utility of radiolabelled drugs and other 
radioligands in vivo before embarking on expensive clinical trials. In developing new PET 
radioligands, a common reason for candidate rejection is that the non-specific binding signal obscures 
the specific binding signal and, thus reduces the quality of the PET scan data. A high non-
specific/specific binding ratio is a major reason for radiotracer failure and there is no completely 
satisfactory predictor of its magnitude. Non-specific binding is a poorly understood phenomenon but 
is believed to be related to the binding of labelled molecules to tissue membranes.  
 
A series of Spiperone analogues have been synthesised and tested in a variety of biophysical assays to 
increase the understanding of the molecular basis of drug-lipid interactions. Rapid cyclic voltammetry 
experiments were also performed to examine the interaction of drugs with a DOPC monolayer on a 
Pt/Hg electrode. The Spiperone analogues were tested in this system and the larger molecules were 
shown to have a larger interaction with the DOPC monolayer. A set of well characterised central 
nervous system drugs were also tested in this system and it was found that the strength of their 
interaction has a strong correlation with the measured in vivo non-specific binding.  This technique 
could therefore be used to screen candidate drugs and radioligands to predict their non-specific 
binding. An assay that can select compounds that display the greatest likelihood of success would be 
extremely valuable due to the high cost and low-throughput nature of PET imaging. 
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 4 Abbreviations 
 
AU Arbitrary units  
β Beta particle 
BBB Blood-Brain Barrier 
CAD Cationic Amphiphilic Drug 
CCD Charge-coupled device 
CHI Chromtographic Hydrophibicity Index 
CHI_IAM Chromtographic Hydrophibicity Index of the immobilised artificial 
membrane 
CNS Central nervous system 
Cryo-TEM Cryo-transmission electron microscopy 
CSA Cross sectional area 
C12E8 Octaethylene glycol monododecyl ether 
DCM Dichloromethane 
DiLS Diamond Light Source 
DFT Density functional theory 
DLS Dynamic light scattering 
DLPC 1,2-dilauroyl-sn-glycero-3-phosphocholine 
DMPC 1,2-dimyristoyl-sn-glycero-3-phosphocholine 
DMSO Dimethyl Sulfoxide 
DOPC 1,2-dioleoyl-sn-glycero-3-phosphocholine 
DOPE 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine 
Eint Interaction energy 
ELSD Evaporative Light Scattering Detector 
Em Emission wavelength 
ESRF European Synchrotron Radiation Facility  
Ex Excitation wavelength  
FA Fatty acid 
GSK GlaxoSmithKline 
GTP Guanosine triphosphate  
HII Inverse Hexagonal phase  
HOMO Highest occupied molecular orbital 
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HPLC High Performance Liquid Chromatography 
II Micellar phase 
IAM Immobilised artificial membrane  
KD Dissociation equilibrium constant 
Lα Fluid lamellar phase 
LA Lauric acid 
LCMS Liquid Chromatography-Mass Spectrometry  
Log D Distribution partition coefficient 
Log P Lipophilicity, partition coefficient 
LPC Monooleoylphosphatidylcholine (lyso-PC) 
LUMO Lowest unoccupied molecular orbital 
MA Mystiric acid 
MANT N-methylanthraniloyl 
µM Micromolar 
mM Millimolar 
M Molar 
MS Mass spectrometry 
MW Molecular weight 
NADPH Nicotinamide adenine dinucleotide phosphate 
nm Nanometer 
NMIA N-methyl Isatoic Anhydride 
NMR Nuclear Magnetic Resonance 
 s Singlet 
 d Doublet 
 m Multiplet 
 t Triplet 
 Hz Hertz 
 δ Chemical Shift 
 ppm Parts per million 
NSB Non-specific binding 
OA Oleic acid 
PAH Polycyclic aromatic hydrocarbon  
PBS Phosphate Buffered Saline 
PC Phosphatidylcholine 
PE Phosphatidylethanolamine  
PET Positron Emission Tomography 
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PI Phosphoinositol 
pKa Acid dissociation constant 
PL Phospholipid 
PS Phosphatidylserine 
PZC Potential of zero charge 
QII Inverse Cubic phase 
QII
D Diamond cubic phase 
QII
G Gyroid cubic phase 
QII
P Pimitive cubic phase 
R Alkyl group 
RCV Rapid cyclic voltammetry  
RT Room temperature 
SAXS Small Angle X-ray Scattering 
TFA Trifluoroacetic Acid 
THF Tetrahydrofuran  
TLC Thin Layer Chromatography 
UV Ultraviolet spectroscopy 
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5 Introduction 
5.1The Cell Membrane 
 
The cell is the basic living structural and functional unit making up a living organism and is made of 
characteristic parts which enable each cell to undertake a unique biochemical and structural role.  
In eukaryotic cells a phospholipid membrane encapsulates and compartmentalises different organelles 
such as the endoplasmic reticulum, the Golgi apparatus, the mitochondria and the nucleus from the 
contents of the cyctoplasm1 and also the cell itself from the extracellular fluid. This 
compartmentalisation allows specific metabolic activities to take place in the cell or in specific 
organelles as pH, ionic strength and electric field gradients can be maintained across a membrane. 
This is especially important in the case of mitochondria which rely on their internal membranes to 
isolate the harmful reactive oxygen intermediates formed during the synthesis of adenosine 
triphosphate (ATP)2.  
The fluid mosaic model of the cell surface (plasma) membrane was first proposed by Singer and 
Nicholson in 19723. In this model ‘icebergs’ of protein are floating in a two-dimensional sea of lipid4. 
Such proteins are called integral proteins because they are integrated into the membrane. Other 
proteins are called peripheral proteins because they associate with the periphery of the membrane as 
shown in figure 5.1.1. 
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Figure 5.1.1 Illustration of the cell membrane. Key features include the lipid bilayer possessing embedded proteins and 
intracellular cytoskeletal filaments5.  
 
5.1.1 Receptors 
 
Receptors are integral proteins which serve as cellular recognition sites which receive specific 
chemical signals. A signalling molecule, known as a ligand, binds to a receptor and a biological 
response is observed. A ligand can be a peptide, neurotransmitter, hormone, drug or toxin6. A ligand 
will travel across intercellular spaces, such as a synapse, bind to a receptor and activate or inhibit the 
receptor’s associated biochemical pathway. Drugs are designed to activate or inhibit a biological 
response and are called agonists and antagonists respectively.  
Receptors can be divided into three classes; ion channels, G-protein coupled receptors, and receptors 
with a single transmembrane unit. Ion channels are homo- or hetero-oligomeric receptors that consist 
of several subunits organised in a ring that forms the channel containing the ligand binding site7. G-
protein coupled receptors interact with guanosine triphosphate(GTP)-binding proteins and consist of 
seven transmembrane helices.  
A receptor is defined by a number of properties. Binding of ligands must be saturable because there 
are a finite number of receptors on the cell surface. A receptor must be specific to a particular type of 
ligand, there should be a correlation between the binding affinity of a series of ligands and the 
biological response in which they exert. It is important that ligands bind reversibly to a receptor so 
once an effect has been induced the ligand can dissociate6.  
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5.1.3 Membrane Curvature 
 
Type I and type II lipids are known as non-bilayer lipids, when immersed in an aqueous solution these 
lipids curve away from or towards the aqueous interface respectively. Type 0 bilayer lipids by 
definition do not curve away from or towards the aqueous interface.  
Type I lipids are those where the cross sectional area (CSA) of the headgroup is larger than the CSA 
of the tails. An example of a type I lipid is a single chained lysolipid (shown in figure 5.1.3 a). When 
they aggregate in aqueous solution they form micelles with ‘positive’ curvature.  In type II lipids the 
CSA of the headgroup is smaller than the CSA of the tails. An example of a type II lipid is 1,2-
Dioleoyl-sn-Glycero-3-Phosphoethanolamine (DOPE) (shown in figure 5.1.3 c)). When type II lipids 
aggregate in water there is a resulting ‘negative’ curvature towards the aqueous solution10. In type 0 
lipids the CSA of the headgroup and tails are approximately equal. An example of a type 0 lipid is 
1,2-Dioleoyl-sn-Glycero-3-Phosphocholine (DOPC) (shown in figure 5.1.3 b)).  
A self-assembled (in the absence of any lateral constraints) bilayer is free to change its molecular area 
(expand or contract laterally) so as to minimize its free energy. Once equilibrium is reached, the sum 
of the forces acting in the plane of the bilayer (lateral pressures) is essentially zero. However, since 
the bilayer is of finite thickness, the various contributions to the total lateral pressure will act at 
different depths. The integral of the stresses across a monolayer are expressed in equation 5.1.1. 
 
∫ ( )     
Equation 5.1.1 
 
Measuring the internal pressure in a bilayer directly is difficult11 but has been modelled12. The 
bending moment, or torque, τ, is a measure of the desire of the monolayer to bend and is expressed in 
equation 5.1.2. This function relates the lateral forces present at different levels through a cross 
section taken normal to the bilayer surface13.  
 
   ∫ ( )      
Equation 5.1.2 
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The shape adopted by lipids depends on the lateral pressure profile (figure 5.1.4 b)) and the 
spontaneous pressure profile. Type 0 lipids are simply those where the lateral pressure is insufficient 
to drive the system into a curved interface.  
 
 
a) b) c) 
   
Figure 5.1.3 Examples of lipid shapes. a) type I lipid, b) type 0 lipid, and c) type II lipid. Picture taken from a paper by Ces 
and Mulet13.  
 
 
When incorporated in a bilayer membrane both the type I and type II lipids impart a desire for 
interfacial curvature  because of the non-uniform distribution of lateral pressures between the lipid 
molecules (figure 5.1.4 b))13. Distributions of positive and negative pressures are found through the 
monolayer.  
Figure 5.1.4 a) shows the intermolecular interactions within the bilayer that lead to either positive 
(blue) or negative (red) lateral pressures parallel to the bilayer. Modifying parts of the molecule will 
have drastic effects on the lateral pressure profile. For example, if the number of hydrocarbon chains 
on each molecule is increased then there will be an increase in the steric interactions in the tail region. 
Varying the shape, size, hydrophilicity and hydrogen bonding in the head-groups will alter the 
repulsive forces at or around the polar to non-polar interface region.  
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a) b) 
  
Figure 5.1.4 a) The various lateral forces acting upon a lipid bilayer and b) a lateral pressure profile demonstrating 
the attractive and repulsive forces present across an amphiphilic monolayer. Picture taken from a paper by Ces and 
Mulet 13.  
 
 
When considering large scale bilayers10 the bilayer is considered to be a simple elastic sheet as the 
layer thickness is negligible compared to the other dimensions of the bilayer. Two principal 
curvatures, c1 and c2, are needed in order to provide a descriptive analysis of the curvature of a 
membrane and are equal to the inverse of their principle radii of curvature, R1 and R2 respectively. R1 
and R2 are shown in figure 5.1.5. The bilayer is characterised by its mean and Gaussian curvatures, H 
and K. These are related to the principal curvatures c1 and c2 at a given point P on the surface, as 
shown in equations 5.1.3 – 5.1.4 and figure 5.1.5.  
 
 
  
[     ]
 
 
 
Equation 5.1.3 The mean curvature.  
 
 
 
 
              
Equation 5.1.4 The Gaussian Curvature.  
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Figure 5.1.5 Definition of mean curvature H and Gaussian curvature K for a lipid monolayer.  R1 and R2, and c1 and 
c2, are the principal radii of curvature, and the principal curvatures, respectively, at the point P. Type I systems and type II 
systems are shown8. 
The energy associated with changing the mean or Gaussian curvature is dependent upon the 
isothermal bending modulus, κ (which relates to the rigidity of the monolayer), the Gaussian 
curvature modulus κG (which relates to the monolayer stiffness to being stretched in a lateral 
direction) and to the spontaneous curvature, c0 (which relates to the desire of the monolayer curling 
away from being flat).   
The curvature elastic energy per unit area (gc) at a given point is defined in equation 5.1.5
13. The term 
H0 describes the spontaneous mean curvature when a surface is relaxed. The constants in equation 
5.1.5 differ from amphiphile to amphiphile or as a function of lipid composition.  
 
gc  = 2κ (H-H0)
2 + κGK 
Equation 5.1.5 The Helfrich Hamiltonian 
 
For a flat monolayer K and H are zero meaning that gc = 2κH0
2 (the stored curvature elastic stress). In 
the above equation the first term quadratic in H expresses the energy cost of deforming the monolayer 
away from the equilibrium mean curvature and the second term gives the contribution to the free 
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energy of the Gaussian curvature of the monolayer. The spontaneous curvature, the curvature at which 
the curvature free energy of the system is at a minimum, is the curvature at the lipid water interface 
that would be adopted by the monolayer in the absence of any constraints13.  
 
 
a) b) c) 
 
Figure 5.1.6 Diagram ilustrating the creation of a vacuum when the bilayer deviates from the planar structure14.  
 
 
The membrane possesses stored curvature elastic stress when, due to the geometry of the amphiphiles, 
it would bend towards (figure 5.1.6 a)) or away from (figure 5.1.6 c)) the aqueous region but cannot 
do due to the energetic costs of forming a vacuum. Membrane curvature is generated as a result of 
complex interplay between membrane proteins, lipids and physical forces that are applied to the 
membrane surface15. To control membrane curvature, cells have sensors that feed back to the 
curvature-inducing molecules. Previous studies16 have shown that the stored curvature elastic stress in 
the lipid membrane’s monolayer modulates the activity of CTP: phosphocholine cytidylyltransferase, 
the results show how a purely physical feed-back signal could play a key role in the control of 
membrane lipid synthesis.  
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5.1.4 Lipid Phase Behaviour 
 
Many biological functions and processes are associated with the adoption of complex geometries by 
cellular membranes1. Lipids adopt different types of liquid-crystal phases in water. The phase adopted 
results from an optimization of the hydrophobic effect with a variety of intra- and intermolecular 
interactions, in combination with a number of geometric packing constraints10. The geometrical 
packing constraints are due to the types of lipid present and the level of hydration. If the energetic 
driving force for interfacial curvature towards the aqueous region becomes sufficiently strong, a 
transition will tend to occur from the fluid bilayer lamellar phase to an inverse phase, where there is 
negative monolayer interfacial mean curvature1.  
Lysolipids and fatty acids possess different physicochemical properties compared to those of typical 
membrane lipids, this makes them interesting to study both biologically and physically.  
When in aqueous solution, lysolipids are non-bilayer forming and pack in highly curved structures17. 
Fatty acids mixed with bilayer lipids such as DOPC form inverse hexagonal structures (HII) that 
consist of an inverted hexagonal structure of parallel cylinders of water bounded by lipid polar groups 
with the space between the cylinders filled by non polar components10 (figure 5.1.7). When the 
concomitant fatty acids are mixed with bilayer lipids such as 1,2-dilauroyl-sn-glycero-3-
phosphocholine (DLPC)  and 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC)  inverse 
structures such as  the inverse hexagonal phase (HII) and inverse cubic phases are formed
18.   
When in high concentrations, fatty acids and lysolipids destabilize the membrane, this can lead to the 
membrane undergoing morphological changes leading to increased permeability19-22 and sensitivity to 
fusion processes23-29. It has also been shown that fatty acids regulate the activity of specific ion 
channels30. Studying the phase behaviour of model lipid systems may help in understanding and 
possibly predicting the interactions between lysolipids, fatty acids, and biological membranes.  
Results in this thesis show the appearance of liquid crystalline inverse bicontinuous cubic phases (QII) 
which consist of a single continuous lipid bilayer on either side of which lie two interpenetrating 
continuous networks of water channels31. Some of the most commonly found inverse bicontinuous 
cubic phases adopted by lipids in aqueous solution are shown in figure 5.1.7.  
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5.2 Drug-Membrane Interactions 
 
Biological membranes play an essential role in drug action. A drug has to pass through several 
membrane barriers before it can exert its therapeutic effect. Orally applied drugs are absorbed in the 
intestine, whereas dermal application relies on skin permeation. Other pharmaceuticals have to pass 
the blood–brain barrier (BBB) to reach their molecular targets. To pass through a cell the drug has to 
dissolve in the aqueous phase, get solubilised in the membrane phase, diffuse across the membrane 
core, and afterwards partition again into an aqueous compartment. Therefore, in addition to 
metabolism and physiological potency, the membrane–water partition coefficients (which quantify 
membrane affinity or lipophilicity) are important parameters in modern drug design39. 
 
5.2.1 The Blood Brain Barrier 
 
For central nervous system (CNS) drugs to be effective and to reach their desired target they must 
pass through the BBB. The BBB is comprised of brain capillary endothelial cells that effectively 
isolate the brain from the periphery40.  The vessel walls are fairly impermeable due to the presence of 
tight junctions. Transport mechanisms are prevalent within the capillaries, including efflux pumps 
such as p-glycoprotein (PGP) that function to keep non-essential molecules out of the brain41, 42 and 
other proteins to facilitate passage of important substrates into the brain43. It is well documented that 
non-specific binding of drugs can occur on plasma proteins, cell membranes and other components 
presents in the bloodstream44-49. 
 
Increasing lipophilicity always leads to an enhanced BBB diffusion. However, when lipophilicity 
becomes high enough, low plasma solubility, lung and liver uptake, and non-specific binding to 
plasma proteins serve to reduce free fraction and subsequently lower brain uptake43.Very polar 
compounds normally exhibit high water solubility, fast clearance through kidneys, and often contain 
ionizable functional groups that limit BBB penetration43.  
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5.2.2 Drug Transport Mechanisms  
 
5.2.2.1 Active and Passive Transport 
 
Drug molecules must cross multiple cell membrane barriers to reach their site of action50. 
Conventionally, compounds can pass a biological membrane by either active transport or passive 
transport. 
Passive transport takes place without energy expenditure. One type of passive transport is thought to 
take place via a diffusion mechanism51-53. Molecules can diffuse in any direction across a biological 
membrane. The rate of diffusion is governed by Fick’s First Law of Diffusion; the net flux goes from 
regions of high concentration to low concentration with a magnitude that is proportional to the 
concentration gradient. Drugs can also cross the membrane by diffusion through a channel, the 
opening and closing of which can be controlled by a ligand binding or a change in voltage or 
mechanical stress of the membrane. Figure 5.2.1 shows a schematic of passive diffusion. Passive 
transport exhibits low structural specificity and is driven by a concentration gradient across the 
membrane spanning two compartments.  
Passive transport is non-saturable and is the main mechanism by which the majority of drugs diffuse 
through the body50. Non-ionised forms or neutral drugs like caffeine will readily cross 
the membrane by diffusion54. The proportion of ionised drug to non-ionised drug is dependent on the 
pKa of the drug and the pH of the medium on either side of the membrane. It is thought that cationic 
amphiphilic drugs (CADs) (discussed later in section 5.2.2.2), which are amphiphilic bases, would not 
cross a membrane by diffusion alone2. If the CAD enters the cell or crosses the BBB by simple 
diffusion it is likely to become protonated in the intracellular environment as the pH of arterial blood 
plasma is ~7.4, cerebrospinal fluid ~7.3 and cystosol ~ 7.255. Once the drug has entered the cell it is 
unlikely to diffuse out of the cell due to it being in the protonated state.  
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Figure 5.2.1 A schematic of passive transport through a phospholipid bilayer. Picture taken from paper by Seddon et 
al2.  
 
Compounds that are recognized as being essential by specific biological receptors normally pass 
through the biological membrane via active transport. These compounds are pumped by systemic 
circulation into tissue against the concentration gradient. This net flux against the concentration 
gradient requires cellular energy in the form of ATP56. The energy is expended by the cell in 
processes such as endocytosis, carrier-mediated transport or the use of specific efflux receptors50.  
 
5.2.2.2 Lipid Hydrolysis 
 
Another proposed drug transport mechanism is the acid catalysed degradation of the phospholipid 
bilayer that forms cell membranes50, 57 by a class of drug molecules called CADs. CADs normally 
consist of a secondary and/or tertiary nitrogen, which is protonated at physiological pH, a modest 
mass (~250 – 450 Da) and high levels of hydrophobicity. These structural properties are essential for 
membrane degradation50. Two examples of CADs, Spiperone and Haloperidol, are shown in figure 
5.2.2.  
a) b) 
 
 
Figure 5.2.2The structures of typical CADs. A) Spiperone b) Haloperidol.  
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It has been shown that Haloperidol50 and a range of other CADs catalyze the hydrolysis of ester 
linkages within membranes composed of phospholipids such as DOPC, releasing a lyso-lipid (in this 
case, monooleoylphosphatidylcholine (LPC)) and a fatty acid, oleic acid (OA)57. However, there is a 
strong variation in the degradation rate of CADs. The amount of hydrolysis observed confirmed that 
the mechanism must be catalytic, with respect to Haloperidol, because the extent of degradation 
exceeded that which could be due to a stoichiometric reaction57. 
The LPC generated then forms phase-separated micelles and membranous fragments on either side of 
the parent membrane50. CADs resident in these fragments are then transported to another membrane 
interface to undergo the same process again50 (figure 5.2.4). 
 
 
Figure 5.2.4 Schematic depicting the proposed mechanism of drug transport. (a) the drugs, shown as black ovoids, are 
introduced to a DOPC bilayer (where the lipids are depicted as light grey spheres with ‘tails’), (b) to which they bind; (c) 
CAD-catalyzed hydrolysis of DOPC leads to the formation of LPC (dark grey regions); (d) over time, LPC accumulates; and 
(e) as the concentration of LPC increases, micelles will bud off. Incorporation of the drug molecules within the micelles and 
subsequent binding to a different membrane leaflet results in drug translocation. Picture taken from a paper by Casey57. 
 
The CADs’ small size (relative to the lipid chain) mean that their inclusion in the phospholipid bilayer 
is easy and results in a reduction of  the stored membrane curvature elastic stress (described in section 
5.1.3) by allowing lipid chain splay to occur50. The stored curvature elastic stress of the membrane 
increases due to the change in lipid composition brought by CADs. The intercalation of CADs 
between such stressed membrane components can relieve the stored curvature elastic stress within the 
membrane and is thus an energetic driving force for this process61 and their incorporation further 
increases the rate of degradation. This has been demonstrated in a previous study, where saturated 
lipids with a shorter acyl chains (and so a reduced stored curvature elastic stress) had much lower 
rates of hydrolysis50.  
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It is hypothesised that by hydrolysing the membrane and budding off in micelles as shown in figure 
5.2.4., the CADs have a higher chance of binding to their desired target. CADs that exhibit a higher 
rate of membrane hydrolysis will reach their desired target more frequently and it is thought will have 
a lower level of non-specific binding.  
Small angle x-ray scattering (SAXS) and high performance liquid chromatography (HPLC) (described 
in sections 7.1.1 and 8.1.1 respectively) are used in this work to deduce the composition of a 
DOPC:CAD system over time and so the extent of membrane hydrolysis.  
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5.2.3 Lipophilicity 
 
5.2.3.1 What is Lipophilicity and why is it Important?  
 
The lipophilicity of a compound is quantified as the partition coefficient, Log P and is measured as 
the ratio between the concentration of a drug present in an organic solvent layer and the concentration 
of a drug present in an aqueous buffer at equilibrium62 as shown in equation 5.2.1.  
 
      
    [                            ]
    [                     ]
 
Equation 5.2.1 Calculating Log P.  
 
A compound’s lipophilicity is one of the most important and fundamental measurements in the area of 
drug and radioligand design and development63. It is a fundamental physiochemical property that 
plays a crucial role in the absorption, distribution, metabolism, and elimination of therapeutic drugs64.  
Lipophilicity is often used to help predict delivery of a radioligand to the desired organ e.g. cross the 
BBB, and to anticipate the rate of clearance from non-target tissues65. It has also been shown that 
there is a correlation between the lipophilicity of a molecule and its overall bioactivity within the 
body66.  
Often a parabolic relationship is observed between the lipophilicity of a drug and brain penetration, 
where drugs with an intermediate lipophilicity exhibiting the highest uptake67. This indicates that 
drugs with a high lipophilicity will have a reduced uptake in the brain. This is because drugs with a 
high lipophilicity have low plasma solubility, increased lung and liver uptake and higher non-specific 
binding values64. 
It has been stated that generally if a molecule has a lipophilicity between Log p = 1.5 and Log p = 3, it 
will have the potential to be a good radiotracer in positron emission tomography (PET) imaging, with 
low non-specific binding2, 64, 68, 69 (discussed in section 5.2.4).  In this range the molecule is lipophilic 
enough to allow BBB permeation, whilst having a low enough lipophilicity as to have a minimum 
amount of non-specific binding in vivo.  
The lipophilicity of compounds that can be ionised at various pHs is recorded as Log D. Log D is a 
pH-dependent partition coefficient and is the ratio of the log of the concentration of a compound in 
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the n-octonal phase and the water phase at a given pH. Log D differs from Log P in that it accounts 
for all neutral and charged species present whereas Log P is used for neutral molecules only. The Log 
D at pH 7.4 is the preferred gold standard measure of lipophilicity when designing radiotracer 
candidates68. 
 
5.2.3.2 Measuring Lipophilicity 
 
Log P can be calculated in various ways including computational based methods, liquid/solid 
measurements or the most commonly used method being the shake-flask technique70, 71. The ‘shake-
flask’ method involves the addition of the compound of interest to high purity analytical grade n-
octanol and double distilled water. The mixture is then shaken until reaching equilibrium and is 
centrifuged to separate the two components. The concentration of compound in each phase is then 
determine using UV/Vis spectroscopy, gas chromatography or HPLC66 and the ratio of the Log of the 
concentration is recorded as Log P. There are extensive databases available for comparison of Log P 
between different laboratories.  
A HPLC-based system for determining Log D values by measuring the retention time of a compound 
on a C18 column has been developed
62, 72. This methodology has also been used to measure a 
compounds interaction with the bio-mimetic immobilized artificial membrane (IAM) column (shown 
in figure 5.2.5). As a compound passes through the column it is retained, eluting from the column at a 
certain time depending on its lipophilicity. The longer the compound takes to elute from the column, 
the stronger its interaction with the column and the higher its lipophilicity. The measured retention 
times are converted to Chromatographic Hydrophobicity Index (CHI) values that approximate an 
acetonitrile concentration with which the equal distribution of compound can be achieved between the 
mobile phase and the column. The CHI lipophilicity scale differs from the n-octanol/water 
lipophilicty scale because it is sensitive to H-bond acidity of the compounds73.  
Using this method, a minimum amount of compound is needed. The system is able to handle mixtures 
and measurements can be performed very quickly and easily. This method also prevents impurities 
and low solubility affecting the results as impurities and solvents can be separated from the compound 
of interest71.   
The column used to measure Log D values consists of octadecane (C18H37) groups linked to a solid 
support. The IAM column consists of monolayers of amphiphilic PC lipids covalently bonded to 
aminopropyl silica particles through a terminal amide linkage and is referred to as IAM.PC as shown 
in figure 5.2.5. The IAM column is designed to simulate the cell membrane and mimics interactions 
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5.2.4 Non-Specific Binding 
 
PET is an imaging modality used to image the distribution and localisation of a radioligand in the 
body75. It is also used to quantify the binding of ligands to receptors by measuring the number of 
binding sites and affinity of a radioligand for a receptor. Drugs are designed to bind to a specific 
target, which is usually a membrane embedded receptor or an enzyme. PET is used in pharmaceutical 
development to establish the utility of radiolabelled drugs and other radioligands in vivo before 
embarking on expensive clinical trials.  
 
Figure 5.2.6 In vivo PET Images showing the specific and non-specific binding of [11C]WAY 100,635 to Serotonin 1A 
receptors in the human brain. The picture on the left is a PET image showing the specific binding of 11C-labelled WAY 
100,635 to serotonin 1A receptors. The central picture is of a PET image showing the homogenous non-specific binding of 
11C-labelled WAY 100,635 (the specific binding of the11C-labelled WAY 100,635 to serotonin 1A receptors is blocked by 
binding of non-labelled “cold” WAY 100,635). The picture on the right is magnetic resonance image showing the brains 
anatomy. Picture reproduced from the Chemical Biology Centre website76.  
 
PET imaging of receptor distribution in vivo has shown that radioligands not only bind to their target 
receptor but also to non-receptor (or non-target) sites. This phenomenon is termed non-specific 
binding and is defined as non-saturable binding to tissue. Non-specific binding has potentially wide-
ranging consequences in explaining why certain compounds make good in vivo imaging agents for 
PET or make effective drugs. A PET image with non-specific binding is shown in figure 5.2.6. 
In developing new PET radioligands, a common reason for candidate rejection is that the non-specific 
binding signal obscures the specific binding signal and, thus, reduces the quality of the PET scan data. 
A high non-specific/specific binding ratio is the main reason for radiotracer failure77 and there is no 
completely satisfactory predictor of its magnitude; however, it has been shown that there is a 
correlation between the degree of non-specific binding and lipophilicity78, 79. There are, however, a 
number of exceptions.  The molecule WAY 100,635 is a PET radioligand for in vivo imaging of the 5-
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hydroxytryptamine1A (5-HT1A)  receptor and has a high lipophilicity yet shows low levels of non-
specific binding80 and the molecule CFT  (2β-carbomethoxy-3β-(4-fluorophenyl) tropane) has a low 
lipophilicity yet a high value of non-specific binding in vivo77. An aim of research into non-specific 
binding is to explain such a discrepancy so that more effective radioligands and drugs can be 
designed. Non-specific binding is a concept that is not widely used in drug development but a drug 
may have hopeful results in vitro but may fail entirely in vivo if it has high non-specific binding. Non-
specific binding of a drug will dramatically affect the dose required for a drug to be therapeutic.  
 
5.2.4.1 Measurement of Non-Specific Binding In Vivo 
 
The ratio of specific/non-specific binding in vivo is calculated by measuring the volume of 
distribution, the ratio of a compound’s concentration between tissue and plasma at equilibrium. By 
comparing the volume of distribution of a compound in a region of high receptor concentration with 
that of a region devoid or with a very low density of the receptor, non-specific binding can be 
accurately quantitated81.   
In vivo non-specific binding values are obtained by fitting the curve of the radioactivity concentration 
as a function of time in regions of interest (ROIs)82.  
The binding parameters for the quantification of PET imaging data are derived using the three- 
compartment model83 which is the most widely used model. This binding model reduces the 
complexity of the radioligand behaviour in any ROI by considering the radiotracer moving across 
three compartments shown in figure 5.2.7.  
 
 
Figure5.2.7 Three-compartment model for radioligand binding82. Ca is the concentration of unmetabolised radioligand in 
plasma. C2 is the concentration of free and non-specifically bound radioligand in the region of interest (ROI). C3 is the tracer 
concentration specifically bound to the molecular target in the region of interest. K1 and k2 describe the transport of the 
ligand from plasma to brain and vice versa, respectively; k3 and k4 are the rates of association and dissociation to and from 
the receptors, respectively.  
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The first compartment corresponds to the concentration of unmetabolised radioligand in the 
plasma, Ca. In the plasma, the transfer between free radioligand and radioligand bound to plasma 
proteins is assumed to be rapid. If f1 is the measured fraction of free radioligand in plasma, f1Ca is the 
concentration of the non-protein bound tracer in plasma that crosses into tissue.  
The second compartment corresponds to the concentration of free and non-specifically bound 
radioligand in the ROI, identified as the non-saturable component of the total tracer regional binding 
in the tissue, C2.  
The third compartment corresponds to the tracer concentration specifically bound to the receptor 
target in the ROI, C3. The concentrations in each compartment are by definition homogeneous and it 
is assumed that radioligand transfer from plasma to tissue is by diffusion only.  
The first-order rate constants (K1, k2, k3, k4) describe the exchange of radioligands between these 
compartments, as shown in figure 5.2.7.  The volume of distribution is an important parameter to 
obtain from in vivo PET studies and the equilibrium distribution volume of a compartment i, is 
defined in equation 5.2.2 
 
    
  
    
         
Equation 5.2.2 Calculating the volume of distribution.  
 
In a region with specific binding sites, the total distribution volume (VT) for that region is VT = V2 + 
V3, in a region devoid of binding sites VT = V2. VT refers to the total volume of ligand uptake relative 
to the concentration of ligand present in the plasma measured in mlg-1.  
Several methods are available to obtain distribution volumes from the PET scan data. Kinetic analysis 
consists in finding the set of rate constants that best fit the PET time–activity curves in the ROIs. 
Because the model is linear, the rate of flux is described by equations 5.2.3 and 5.2.4.  
 
   ( )
  
      ( )   (      )  ( )       ( ) 
Equation 5.2.3 
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      ( )       ( ) 
Equation 5.2.4 
 
The radiotracer is administered at time t = 0, therefore C2(0) = 0 and C3(0) = 0. At equilibrium, the 
distribution volumes are then derived by using equations 5.2.5 and 5.2.6.   
 
    
  
    
  
  
    
 
Equation 5.2.5 
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Equation 5.2.6 
 
The modelling estimate of the non-specific binding in in vivo PET experiments is defined as V2-1, 
where V2 is the distribution volume in the nonspecific and free compartment.  
 
5.2.4.2 Measurement of Non-Specific Binding In Vitro 
 
The development of radioligands and drugs will lead to a series of compounds as potential ligands for 
in vivo investigation using PET imaging. Screening each candidate in a series of lead compounds in 
vivo can be both costly and time-consuming so lead compounds are identified using in vitro studies.  
The magnitude of non-specific binding in vitro can be measured using receptor-ligand binding assays 
using live cells and homogenized tissue samples84. Specific binding of a radioligand to a receptor is 
characterized by a saturation profile (figure 5.2.8) where the specific sites are all filled by the 
substrate. Non-specific binding is typically measured in a competitive binding assay by measuring 
radioligand binding in the presence of a saturating concentration of an unlabelled ‘cold’ ligand that 
binds to the same receptor. The unlabelled ligand occupies virtually all the receptors so the 
radioligand binds only non-specifically. The non-specific binding is then subtracted from the total 
binding at saturating concentration of unlabelled ligand to calculate the specific radioligand binding to 
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receptors85, as shown in figure 5.2.8. Specific binding is a saturable process and non-specific binding 
is typically non-saturable. 
 
a) b) 
 
Figure 5.2.8 a) Graph showing total and non-specific binding b) Graph showing specific binding on a logarithmic scale. 
Image taken from The Graph Pad Guide85.  
In vitro non-specific binding can also be measured using tissue autoradiography. Tissue sections are 
incubated in buffer and radioligand (c.f. ex vivo autoradiography, radioligand is administered into the 
circulation of a live animal with subsequent tissue removal and sectioning), the section is then 
contacted on an detector layer such as a photographic emulsion, film, phosphor imaging plates or 
direct imagers/counters. The radioligand binding is measured as the photo-stimulated luminescence 
per mm2 over the regions of interest as described by Ishiwata et al86.   The same β emitting 
radionuclides used in PET imaging can be used in autoradiography and the same labeling protocol 
employed. The non-specific binding is calculated by measuring radioligand binding in the presence of 
a saturating concentration of an unlabelled ligand that binds to the same receptor87. 
Autoradiography has a better spatial resolution than PET and allows the measurement of tissue 
activity with a spatial resolution that is of the order of less than a few hundred microns. A 
disadvantage of autoradiographic methods is that experimental animals can be studied only once. 
Longitudinal studies and kinetic studies require the use of multiple animals, adding the interanimal 
variability to other sources of variability. The use of a PET scanner allows the tissue concentration of 
radioligand to be measured over time meaning that the temporal history of the radioligand can be 
measured in the same subject88.  
In a living system, however, many factors can reduce the efficacy of a radioligand or drug compound, 
which can result in increased levels of non-target tissue uptake i.e. increased levels of non-specific 
binding, leading to reduced PET image resolution and/or unwanted toxicity. The identified lead 
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compound(s) may not be successful in vivo, as in vitro assays are only models for a considerably more 
complex scenario in vivo.  
 
5.2.4.3 Measurement of Non-Specific Binding In Silico 
 
Ab-initio computational calculations have been performed to increase the understanding of non-
specific binding by investigating the molecular basis of ligand-membrane interaction89, 90. The drugs 
tested in this study were ten well studied CNS drugs (shown in section 6.1.1) which act on a diverse 
range of receptor and enzyme targets.   
The results showed that the drugs with stronger lipid interactions possessed a higher non-specific 
binding value measured in PET imaging. The water-octanol partition coefficient, Log P, for drugs in 
consideration for this study, did not show good predictive power of the in vivo non-specific binding89. 
These findings show that the non-specific binding phenomenon is poorly understood and cannot be 
predicted by the drugs lipophilicity.  
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5.2.5 Measuring Drug-Membrane Interactions 
 
A range of techniques have been used to study the interactions of drugs with membranes both in 
vitro and in vivo; these are detailed in a review by Seddon et al2.  The advantages and disadvantages 
of the various techniques are also discussed. 
In this work several techniques have been used to probe the interaction of the drugs discussed in 
section 6 with lipids. SAXS and HPLC have been used to study the hydrolysis of lipids in 
multilamellar vesicles (discussed in chapter 7 and sections 8.3.2 and 8.4). HPLC has also been used to 
determine the lipophilicity of drugs (discussed in section 8.3.3) and their interaction with an 
immobilised artificial membrane. A fluorescence-based assay has been developed to investigate the 
interaction of drugs with unilamellar vesicles (chapter 9). Finally, rapid cyclic voltammetry (RCV) 
has been used to study the interaction of drugs with a lipid monolayer (chapter 10).  
 
5.3 Aims   
 
One aim of this project was to develop a set of assays that measure the magnitude of a CADs 
interaction with a lipid membrane and determine what effect systematic changes to the CADs 
structure have on this interaction.  
Another aim was to develop a method of measuring the interaction of a set of well characterised PET 
radioligands with a membrane and to ascertain if the results correlate with the in vivo non-specific 
binding observed in a PET scan. The assays developed will hopefully be used, along with other assays 
and measurements, to predict the magnitude of the non-specific binding of a drug or radioligand 
before PET experiments are performed. An assay that can select compounds that display the greatest 
likelihood of success would be extremely valuable due to the high cost and low-throughput nature of 
PET imaging.  
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6 CADS for Investigation 
 
6.1 Introduction 
 
The following compound’s interactions with lipids were investigated using several techniques to place 
them into a rank order of membrane binding affinity. For the CNS drugs these results were compared 
with the in vivo and in silico data previously reported82. The synthesised Spiperone analogue series 
detailed below were designed to investigate the relationship between lipophilicity and the size of the 
molecule with membrane binding affinity and rates of DOPC hydrolysis. This could potentially 
increase the understanding of the non-specific binding phenomenon and of membrane binding on a 
molecular level.  
 
6.1.1 Central Nervous System Drugs  
 
In this study eight of the ten well characterised CNS drugs described in section 5.2.4.3 were 
investigated, the other two drugs, MDL 100907 and N-propylnorapomorphine, were not used due to 
cost and licensing reasons. The eight CNS drug structures are shown in figure 6.1.1.  
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6.3 Synthetic Results 
 
6.3.1 SpipC0me 
 
2.00 g (11.29 mmol) of N-methylisatoic anhydride, 2.61 g (11.29 mmmol) of 1-phenyl-1,3,8-
triazaspiro-[4,5]-decan-4-one and 3.68 g (11.29 mmol) of Ce2CO3 were dissolved in  ~ 200ml of dry 
THF and heated to 70°C under a reflux condenser and a nitrogen atmosphere for 4 hours. The solvent 
was removed under reduced pressure leaving a brown solid. This was then dissolved in ~100ml of 
DCM and ~20ml of 5% NaHCO3. The organic layer was kept and washed twice with 5% NaHCO3 
and dried with MgSO4. The DCM was removed using reduced pressure leaving a brown solid. The 
crude product was purified using a silica gravity column and a mobile phase of DCM:MeOH resulting 
in 709 mg (17 % yield) of a white / yellow solid. The white solid was then characterised using 1H 
NMR, MS, LC-MS and TLC which showed the product to be >95% pure.  
 
1H NMR [CDCl3] δ = 1.78 (m, 2H, broad); 2.61 (m, 2H, broad); 2.88 (d, 3H); 3.51 (d, 2H); 3.78 (m, 
2H, broad); 4.79 (s, 2H); 5.13 (m, 1H); 6.38 (s, 1H); 6.70 (m, 2H); 6.83 (d, 2H); 6.92 (t, 1H); 7.12 (m, 
1H); 7.30 (m, 3H); ppm. MS (ES+): [M+H]+  365 m/z.  
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6.3.2 SpipC2me 
 
1.78 g (7.94 mmol) of 2-(boc-amino) ethyl bromide, 1.84 g (7.94 mmol) of 1-phenyl-1,3,8-
triazaspiro-[4,5]decan-4-one and 2.58 g (7.94 mmol) of Ce2CO3 were dissolved in ~ 100ml of dry 
MeCN and heated to 80°C under a reflux condenser and for 4 hours. The solvent was removed under 
reduced pressure leaving a yellow/white solid. The crude product was purified using a silica gravity 
column and a mobile phase of DCM:MeOH resulting in a yellow / white solid which was 
characterised using 1H NMR, MS and TLC. 
 
The yellow / white solid was then dissolved in ~50ml 1:1 DCM:TFA and stirred for 2 hours. The 
solvents were removed under vacuum leaving a sticky pink solid, which was washed with 0°C i-PrOH 
to leave a grey / purple solid. This was then left in a vacuum dessicator over night resulting in a dry 
white / pink solid which was characterized using 1H NMR and MS and TLC.  
 
0.60 g (1.54 mmol) of this white-pink solid, 0.27 g (1.54 mmol) of NMIA and 0.22ml (1.54 mmol) of 
triethylamine were dissolved in ~ 50ml of dry THF and heated to 70°C under a reflux condenser and a 
nitrogen atmosphere for 2 hours. The solvent was removed under reduced pressure leaving a yellow / 
brown solid. This was then dissolved in ~100ml of DCM and ~20ml of 5% NaHCO3. The organic 
layer was kept and washed twice with 5% NaHCO3 and dried with MgSO4. The DCM was removed 
using reduced pressure leaving a brown solid. The crude product was purified using a silica gravity 
column and a mobile phase of DCM:MeOH resulting in 45.8 mg  (3 % overall yield) of a white solid. 
This solid was characterized using 1H NMR, LC-MS and TLC which showed the product to be >95% 
pure.  
 
1H NMR [(CD3)2SO] δ = 1.56 (d, 2H); 2.53 (m, 2H); 2.55 (m, 2H); 2.73 (m, 2H); 2.76 (d, 3H); 2.81 
(m, 2H); 4.57 (s, 2H); 6.58 (t, 1H); 6.64 (d, 1H); 6.72 (t, 1H); 6.83 (d, 2H); 7.15 (t, 2H) 7.31 (t, 1H); 
7.53 (m, 1H); 7.58 (m, 1H); 8.21 (t, 1H); 8.63 (s, 1H) ppm.  MS (ES+): [M+H]+  408 m/z. 
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6.3.3 SpipC3me 
 
2.00 g (8.40 mmol) of 3-(boc-amino) propyl bromide, 1.94 g (8.40 mmol) of 1-phenyl-1,3,8-
triazaspiro-[4,5]decan-4-one and 2.74 g (8.40 mmol) of Ce2CO3 were dissolved in ~ 100ml of dry 
MeCN and heated to 80°C under a reflux condenser and for 4 hours. The solvent was removed under 
reduced pressure leaving a yellow/white sticky solid. The crude product was purified using a 
Teledyne Isco Combiflash using a gradient solvent system of DCM and MeOH and silica pre-packed 
columns resulting in a yellow / white solid which was characterised using 1H NMR, MS and TLC. 
 
The yellow/white solid was then dissolved in ~50ml 1:1 DCM:TFA and stirred for 2 hours. The 
solvents were removed under vacuum to leave a sticky grey solid. This was then washed with 0°C i-
PrOH leaving a sticky grey/white solid, which was left in a vacuum dessicator over night resulting in 
a dry grey solid. This was characterized using 1H NMR and MS and TLC.  
 
0.79 g (1.95 mmol) of this grey solid, 0.35 g (1.95 mmol) of NMIA and 0.27ml (1.95 mmol) of 
triethylamine were dissolved in ~ 50ml of THF and heated to 70°C under a reflux condenser and a 
nitrogen atmosphere for 2 hours. The solvent was removed under reduced pressure leaving a brown 
oil.  This was dissolved in ~100ml of DCM and ~20ml of 5% NaHCO3. The organic layer was kept, 
washed twice with 5% NaHCO3 and dried with MgSO4. The DCM was removed using reduced 
pressure to leave a brown solid. The crude product was purified using a Teledyne Isco Combiflash 
using a gradient solvent system of DCM and MeOH and silica pre-packed columns resulting in   410 
mg  ( 12 % overall yield) of a white solid. This solid was then characterized using 1H NMR, LC-MS 
and TLC which showed the product to be >95% pure.  
 
1H NMR [(CD3)2SO] δ = 1.58 (d, 2H); 1.70 (m, 2H); 2.40 (m, 2H); 2.53 (m, 2H); 2.68 (m, 2H); 2.76 
(d, 3H); 2.90 (m, 2H); 4.56 (s, 2H); 6.54 (t, 1H); 6.62 (d, 1H); 6.75 (t, 1H); 6.85 (d, 2H); 7.23 (t, 2H); 
7.28 (m, 1H); 7.52 (m, 1H); 7.64 (m, 1H); 8.30 (t, 1H); 8.63 (s, 1H) ppm. MS (ES+): [M+H]+  422 
m/z. 
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6.3.4 SpipC4me 
 
1.00 g (3.97 mmol) of 4-(boc-amino) butyl bromide, 0.917 g (3.97 mmol) of 1-phenyl-1,3,8-
triazaspiro-[4,5]decan-4-one and 2.59 g (3.97 mmol) of Ce2CO3 were dissolved in ~ 50ml of dry 
MeCN and heated to 80°C under a reflux condenser and for 4 hours. The solvent was removed under 
reduced pressure leaving a yellow gum. The crude product was purified using a Teledyne Isco 
Combiflash using a gradient solvent system of DCM and MeOH and silica pre-packed columns 
resulting in a white solid which was characterised using 1H NMR, MS and TLC. 
 
The white solid was dissolved in ~50ml 1:1 DCM:TFA and stirred for 2 hours. The solvents were 
removed under vacuum leaving a sticky grey solid. This was washed with 0°C i-PrOH to leave a 
sticky grey solid which was left in a vacuum dessicator over night resulting in a dry grey solid. This 
was characterized using 1H NMR and MS and TLC.  
 
0.86 g (2.07 mmol) of this grey solid, 0.37 g (2.07 mmol) of NMIA and 0.29ml (2.07 mmol) of 
triethylamine were dissolved in ~ 30ml of THF and heated to 70°C under a reflux condenser and a 
nitrogen atmosphere for 2 hours. The solvent was removed under reduced pressure leaving a brown 
gum.  This was dissolved in ~100ml of DCM and ~20ml of 5% NaHCO3. The organic layer was kept 
and washed twice with 5% NaHCO3 and dried with MgSO4. The DCM was removed using reduced 
pressure leaving a white / brown solid.  The crude product was purified using a Teledyne Isco 
Combiflash using a gradient solvent system of DCM and MeOH and silica pre-packed columns 
resulting in   244 mg  ( 7 % overall yield) of a white solid. This solid was then characterized using 1H 
NMR, LC-MS and TLC which showed the product to be >95% pure.  
 
1H NMR [(CD3)2SO] δ = 1.57 (d, 2H); 1.70 (m, 2H); 1.90 (m, 2H); 2.73 (m, 2H); 2.76 (d, 2H); 3.17 
(d, 2H); 3.26 (m, 3H); 3.56 (m, 4H); 4.62 (s, 2H); 6.56 (t, 1H); 6.63 (d, 1H); 6.82 (t, 1H); 6.93 (d, 
2H); 7.25 (t, 1H); 7.29 (t, 1H) 7.52 (m, 1H); 7.63 (m, 1H); 8.35 (t, 1H); 9.03 (s, 1H) ppm. MS (ES+): 
[M+H]+  436 m/z. 
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6.3.5 SpipC6me 
 
1.00 g (3.57 mmol) of 6-(boc-amino) hexyl bromide, 0.83 g (3.57 mmol) of 1-phenyl-1,3,8-
triazaspiro-[4,5]decan-4-one and 1.16 g (3.57 mmol) of Ce2CO3 were dissolved in ~ 50ml of dry 
MeCN and heated to 80°C under a reflux condenser and for 4 hours. The solvent was removed under 
reduced pressure to leave a yellow solid. The crude product was purified using a Teledyne Isco 
Combiflash using a gradient solvent system of DCM and MeOH and silica pre-packed columns 
resulting in a yellow solid which was characterised using 1H NMR, MS and TLC. 
 
The yellow solid was then dissolved in ~50ml 1:1 DCM:TFA and stirred for 2 hours. The solvents 
were removed under vacuum to leave a purple/white solid. This was then washed with 0°C i-PrOH 
leaving a white solid which was characterized using 1H NMR and MS and TLC.  
 
0.81 g (2.35 mmol) of this white solid, 0.42 g (2.35 mmol) of NMIA and 0.33ml (2.35 mmol) of 
triethylamine were dissolved in ~ 50ml of THF and heated to 70°C under a reflux condenser and a 
nitrogen atmosphere for 2 hours. The solvent was removed under reduced pressure leaving a yellow 
oil.  This was dissolved in ~100ml of DCM and ~20ml of 5% NaHCO3. The organic layer was kept 
and washed twice with 5% NaHCO3 and dried with MgSO4. The DCM was removed using reduced 
pressure leaving a yellow /white solid. The crude product was purified using a Teledyne Isco 
Combiflash using a gradient solvent system of DCM and MeOH and silica pre-packed columns 
resulting in   187 mg  ( 16 % overall yield) of a yellow / white solid. This solid was then characterized 
using 1H NMR, LC-MS and TLC which showed the product to be >95% pure.  
 
1H NMR [(CD3)2SO] δ = 1.32 (m, 4H); 1.53 (m, 6H); 2.35 (m, 2H); 2.53 (m, 2H); 2.69 (m, 2H); 2.75 
(d, 2H); 2.80 (m, 2H); 3.21 (q, 2H); 4.57 (s, 2H); 6.55 (t, 1H); 6.61 (d, 1H); 6.74 (t, 1H); 6.85 (d, 2H); 
7.23 (t, 2H); 7.27 (t, 1H); 7.51 (m, 1H); 7.63 (m, 1H); 8.26 (t, 1H) 8.64 (s, 1H) ppm. MS (ES+): 
[M+H]+  464 m/z. 
 
Table 6.3.1 shows the name, central carbon chain length, structure and molecular weight of the five 
drugs analogues synthesised. 1H NMR spectra and LC-MS data are shown in the appendix. These 
compounds are novel, or at least unpublished as far as can be ascertained. 
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7 DOPC:LPC:OA Composition 
   Diagram 
 
7.1 Introduction 
 
SAXS has been used to examine the phase and d-spacing of model membrane systems with 
compositions similar to those of cell membranes which will have been hydrolysed by a CAD, namely 
mixtures of DOPC, LPC and OA. This hydrolysis is discussed in section 5.2.2.2.  
Each different phase observed has a characteristic diffraction pattern whereby the diffraction rings 
appear at characteristic ratios (see section 7.1.1); these ratios were measured and the phase and d-
spacing of the lipid mixture deduced accordingly and plotted onto a composition diagram.   
When a DOPC:CAD system is analysed, the phase and d-spacing can be tracked and the composition 
diagram allows the extent of membrane hydrolysis to be deduced. 
 
7.1.1 Small Angle X-Ray Scattering 
 
SAXS can be used to study the phase behaviour of lipids. X-rays are generated by firing a focused 
beam of high-energy electrons, produced from a heated tungsten filament, at a target metal, normally 
copper.  
Upon impact the electrons rapidly decelerate, converting the excess kinetic energy into x-rays via a 
process known as Bremsstrahlung. The emitted x-rays have a range of energies as the electrons do not 
decelerate uniformly. Figure 7.1.1 shows this continuous emission also shows two other characteristic 
peaks.  
When an incoming electron has sufficient energy it is capable of ionising the target metal by ejecting 
one of the inner shell electrons. Another electron from an outer shell immediately moves to fill the 
gap and emits the excess energy as an x-ray. The wavelength of the radiation emitted depends on the 
metal orbitals involved. The most frequent emissions result from M or L shell electrons filling a 
vacated K shell. When the higher energy electron moves from the L shell the resultant radiation is 
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called Kα (figure 7.1.1) and the emission resulting from the M shell transition is called Kβ. For the 
majority of x-ray diffraction studies Kα radiation is used.  
 
 
Figure 7.1.1 X-ray emission spectrum from a copper target99.  
 
X-rays are of approximately the same order of magnitude as the separation between atoms in matter. 
Von Laue combined that fact with the knowledge that many substances consist of a basic unit, 
duplicated and stacked at regular intervals in a three-dimensional array, and theorised that x-rays 
would be scattered by crystalline materials.  
 
Willam L. Bragg showed that the diffraction patterns obtained could also be explained by envisaging 
that the x-rays were being reflected off parallel planes100. A simple diffraction diagram of this can be 
seen in figure 7.1.2, the x-rays are scattered by an angle of 2θ.  
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Figure 7.1.2 Diagram depicting the diffraction of monochromatic, collimated x-rays from a set of lattice planes101. 
 
 
From this, the Bragg equation (equation 7.1.1) can be deduced. 
 
nλ = 2dhklsin θ 
 
Equation 7.1.1 Where n = the order of the reflection, λ = wavelength of radiation, d = spacing between the parallel planes 
defined by the integers h,k and l (miller indices). θ = the angle of incidence.  
 
When the angle of incidence of the x-rays is such that sinθ = nλ/2dhkl, the x-rays are reflected and 
interfere constructively. At a specific incident angle an intense diffraction spot will be observed, and, 
using both the known angle and wavelength of the radiation used the repeat spacing of the crystal (d-
spacing) can be calculated.  
 
Diffraction techniques allow the determination of various lipid phases by examining the symmetry of 
the phase. SAXS examines the diffraction at a low angle from the incident beam, typically 0.1-10° and 
reveals the most information on the phase behaviour of a liquid crystal. Due to the different 
symmetries in the various liquid crystal types, differing sets of rings are produced depending on the 
phases present as shown in table 7.1.1.  Hydrated phospholipid samples contain many liquid crystal 
microdomains that have different orientations, giving rise to circular diffraction patterns102. 
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If the incident beam is vector ki and the vector of the scattered beams ks then a scattering vector, q, can 
be determined by equation 7.1.2102. 
 
| ⃑|     |  ⃑⃑ ⃑⃑     ⃑⃑⃑⃑ |   
  
 
     
 
Equation 7.1.2 
 
The scattering vector is inversely related to the dhkl-spacing by substituting equation 7.1.1 in equation 
7.1.2 to give equation 7.1.3 
 
   (
  
 
) 
 
Equation 7.1.3 
 
The diffraction pattern consists of a set of equally spaced Bragg peaks, 2π/d apart, for each integer, n. 
The scattered intensity is then plotted against d-spacing, as it directly shows the distances between 
phase structures. The reciprocal of them gives rise to the reciprocal spacing Shkl (equation 7.1.4). 
 
      
 
 (     )
 
 
Equation 7.1.4 Where (h,k,l) = the spacing between successive lattice planes, characterised by the Miller indices h,k,l.  
 
The positions of the diffraction peaks I(q) versus a plot of q are then reciprocally related to the d-
spacing in the phase. The sharpness of these peaks is related to the periodicity of these separations 
over large distances and the ratio between the peaks positions allows the long range order of the 
sample to be determined. For liquid crystals, the long range order is affected by molecular motion of 
individual lipids but remains periodic; this causes the diffraction pattern at higher angles (smaller d-
spacing) to decrease with intensity.  
The inverse bicontinuous cubic phases have a three dimensional periodicity and the reciprocal 
spacings of the phase are determined using equation 7.1.5.   
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Equation 7.1.5 
 
Due to symmetry selection rules for the crystallographic space groups Ia3d (QII
G), Pn3m (QII
D) and 
Im3m (QII
P), systematic absences will arise and some Bragg peaks are omitted, so characteristic 
diffraction patterns with peaks at specific ratios are seen. 
 
The lamellar phase consists of a one-dimensional stack of bilayers, so two of the Miller indices are set 
to zero103 and the reciprocal spacings are given using equation 7.1.6.  
 
   
 
 
 
Equation 7.1.6 
 
For lamellar phases, the diffraction pattern will consist of equally spaced concentric rings that will 
index as 1, 2, 3, 4 etc….. The d-spacing (shown in figure 7.1.3) can be determined from the 
diffraction pattern. Most of the time, diffraction from the lamellar phase is well defined and easily 
recognised. Swollen diffuse lamellar phases can also be detected when the lipid system has not yet 
reached equilibrium, and when small molecules such as CADs are added to the system. 
 
 
Figure 7.1.3 Cartoon illustrating the definition of d-spacing in the lamellar phase. 
 
In the lamellar and cubic phase the lattice parameter, a, is equal to the d-spacing. In the hexagonal 
phase the lattice parameter, a, is equivalent to 2/√3 of the d-spacing. The inverse hexagonal phase 
is based on a two-dimensional lattice, therefore the Miller indices for one dimension will be zero 
and the reciprocal lattice can be described by equation 7.1.7.  
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Equation 7.1.7  
 
The peaks in the hexagonal phase index as √1, √3, √4, √7, √9 etc...  
 
 
The normal (HI) and inverted (HII) hexagonal phases have the same diffraction pattern. Figure 7.1.4 
illustrates typical diffraction patterns obtained for a lamellar and hexagonal phase.  
 
 
 
Figure 7.1.4 Characteristic SAXS patterns for a lamellar (left) and a hexagonal phase (right).  
 
The ratios of the rings observed in SAXS patterns of different phases are listed in table 7.1.1.  
 
Table 7.1.1 Ratio of the distance of each ring from the centre of the diffraction pattern for the different phase types10. 
Note that the Fd3m phase has not been observed in this work.  
Phase Ring Ratio 
Lamellar (Lα) 1,2,3,4... 
Hexagonal (HII) 1, √3, √4, √7, √9... 
Ia3d (QII
G) √6, √8, √14, √16, √20... 
Pn3m (QII
D) √2, √3, √4, √6, √8... 
Fd3m √3, √8, √11, √12, √16... 
Im3m (QII
P) √2, √4, √6, √8, √10... 
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Stock solutions of DOPC, LPC and OA were made in chloroform (BDH, 99.8%) at equal 
concentrations. Fractional amounts were then measured by micropipette and transferred to labelled 
vials. Figure 7.2.1 shows the sample naming system used. For example, a sample that has a 
composition of 10% DOPC, 50%LPC and 40% OA is named S9.  
 
 
Figure 7.2.1 Grid showing naming system used for samples.  
 
Once mixed the solution was then gently evaporated under a stream of dry nitrogen, until all the 
chloroform had evaporated and then lyophilized at liquid nitrogen temperature (-196°C). The resulting 
solid was weighed and Milli-Q water added to make the sample up to 2/3 mass by water. This amount 
of water was used as using higher proportions than this does not cause the lipid phases to swell (d-
spacing increase); the lipids are fully hydrated. All samples were prepared in glass vials and stored at 
-20°C when not in use.  
The sample was then subjected to five freeze-thaw-vortex cycles, placed in a 1.5mm diameter thin 
walled x-ray capillary (Capillary Tube Supplies Ltd.), and then centrifuged to the base. The capillaries 
were flame sealed and a silicon sealant plug (Dow Corning Corp.) was applied to ensure airtight 
sealing, which is required to maintain the excess water hydration level. The sample mass was 
typically between 5 and 10 mg. 
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The sample was then placed into an x-ray beamline for analysis. Data were acquired at 37°C allowing 
five-ten minutes of equilibration time at this temperature before exposure (typically 60 seconds). The 
images generated were then analysed as described in section 7.2.3. The phase and d-spacings (defined 
in section 7.1.1) were determined for each sample and the phase observed was then plotted onto a grid 
(figure 7.2.1). 
The composition diagram produced herein is a combination of results from several different studies104, 
105 and work carried out on three different beamlines (see section 7.2.2).  
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7.2.2 Beamlines 
 
SAXS measurements were made in-house on the BEDE beamline, and at two synchrotron beamlines, 
the Diamond light source (DiLS) and the European Synchrotron Radiation Facility, Grenoble, France 
(ESRF). 
Synchrotrons are cyclic particle accelerators, in which electrons are circulated and accelerated by 
alternating magnetic and electric fields respectively. The electrons are injected into a storage ring 
where they circulate and their energies kept constant. When the electrons are deflected from their path 
by a magnetic field they lose energy by emitting a beam of x-rays. Beamlines tangent to the ring can 
capture the projected radiation.  
Synchrotron radiation is more powerful in analysing liquid crystal samples than bench beamlines 
since their photon flux is many orders of magnitude higher, the focal spot size is smaller and they 
have sensitive charge-coupled device (CCD) detectors.  
 
7.2.2.1 Bede Beamline 
 
A schematic of the BEDE beamline set up is shown in figure 7.2.2. The BEDE beamline consists of a 
Bede Microsoure™ Generator (figure 7.2.2 a)), a low power, high flux (~ 106 – 108 photons/s) copper 
target x-ray generator operating at 80 W (40kV, 2mA). Monochromation is achieved via nickel filters, 
a longpass filter, with its absorption edge at 1.49 Å, which removes Kβ radiation leaving solely Kα 
(1.542 Å). Collimation is achieved through integrated XOS glass polycapillary focusing optics and 
100, 200 and 300 mm pinholes (figure 7.2.2 b), resulting in a beam with low divergence, 2mrad.  
The custom built sample chamber (figure 7.2.2 c) is capable of accommodating both 1.5mm glass 
capillaries and Teflon spacers, and can create a local temperature of 2°C to 80°C through a Peltier-
driven heating/cooling system with pt-100 temperature sensor. The flight tube (figure 7.2.2 d) can be 
exchanged for different lengths according to the diffraction angle being investigated.  
Diffraction patterns are imaged on a Photonic Science Ltd Gemstar intensified CCD detector (figure 
7.2.2 f)), detailing images in 1300 x 1030 pixels. X-ray beams hit the phosphor screen and are 
converted into visible light. These photons are then amplified by an image intensifier and are then 
detected by a CCD chip. The detector has a 100 ms readout, and produces ~8 full size images every 
second. To generate images of sufficient resolution, exposure times of between 30 and 150 seconds 
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are typically required. The main x-ray beam was stopped by a lead beamstop attached to a Kapton 
film window (figure 7.2.2 e) just before the detector to avoid over saturation.  
Temperature and image acquisition are controlled from the beamline PC via ‘Scorpion’ K-4 micro-
controller electronics. This provides <0.5°C calibrated accuracy with a read and control accuracy of 
<0.1°C. Shutters are manually operated from the generator control box.  
 
 
Figure 7.2.2 The BEDE Beamline. a) Microsource x-ray generator b) optics and pinholes c) sample chamber d) flight tube 
e) beamstop on Kapton film f) CCD detector. The red line represents the main x-ray beam and the blue line the scattered x-
rays.  
 
7.2.2.2 High Brilliance Beamline ID02 at the ESRF 
 
The experiments carried out at the ESRF were performed on the ID02 beamline (schematic shown in 
figure 7.2.3). X-rays are produced by a triple undulator source which gives extremely high photon 
flux. The x-ray beam is monochromated by a liquid nitrogen-cooled Si-111 monochromator and 
focused by a Rh-coated double focusing toroidal mirror. The monochromator can select wavelengths 
between 1.55 Å and 0.73 Å. The X-ray beam has a wavelength of  λ = 0.7514 Å with dimensions 200 
µm x 400 µm and a typical flux of 4 x 1013 photons/s. 2-D diffraction images were recorded on an 
image-intensified CCD detector consisting of an X-ray Image Intensifier lens (Thomson TTE) 
coupled to a FreLoN (Fast Readout, Low-Noise) CCD device developed at the ESRF. The CCD has 
an active area of 220 mm and a frame rate of just under 10 frames per second (1024 x 1024 pixels).  
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Figure 7.2.3 Schematic of the ID02 beamline at the ESRF. The x-ray source is beyond the undulators, which produce a 
high flux of x-rays. The x-rays are focussed by a toroidal mirror onto the sample and the detector is placed beyond the 
sample to detect the diffracted x-rays.   
 
7.2.2.3 I22 Beamline at the Diamond Light Source 
 
The experiments carried out at the DiLS, Oxfordshire were performed on the ID22 beamline 
(schematic shown in figure 7.2.4). The experiments used a beam of wavelength λ = 1.00Å with 
dimensions 320 µm x 250 µm and a typical flux of  1014 photons/s. 2-D images were recorded on  the 
Refined ADC Per Input Detector system (RAPID) which was developed by the Central Laboratory of 
the Research Councils (CCLRC). The RAPID detector is a 2-D photon-counting gas wire detector 
with high time resolution and low noise.  
 
 
Figure 7.2.4 A schematic of the ID22 beamline at the DiLS. The x-ray source is beyond the undulators, which produce a 
high flux of x-rays. The x-rays are focussed by Kirkpatrick-Baez mirrors onto the sample and the detector is placed beyond 
the sample to detect the diffracted x-rays106.   
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7.2.3 Image Analysis 
 
All data collected were analysed through the in-house software programme known as AXcess, 
designed by Andrew Heron107. The centre of the image is found (figure 7.2.5 a) and the diffraction 
pattern is integrated radially through a user defined section in order to visualise a one-dimensional 
plot of intensity versus pixel number. The resulting peaks are then identified via Gaussian or 
maximum value fitting within user defined constraints as shown in figure 7.2.5 b.  
 
As discussed in section 7.1.1, each of the lyotropic phases gives rise to a characteristic diffraction 
pattern based upon the repeated unit cell of the phase. The phase is determined by indexing the 
sequence of diffraction peaks against the known index patterns.  
 
The peaks are indexed to allow the symmetry of the phase to be deduced. To ascertain if the correct 
phase has been identified a plot of index number versus pixel number must be linear. Figure 7.2.6 a 
shows the indexing of a lamellar phase. The diffraction peaks are evenly spaced and indexing as 1, 2, 
3... against pixel number  produces a linear plot, shown in figure 7.2.6 b.  
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a) 
 
b) 
 
 
Figure 7.2.5 a) SAXS image of Agbe and finding the centre of the image b) indexing the radially integrated peaks.  
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Having calculated the sample-to-detector distance, A, it is now possible to calculate the scattering 
angle, θ΄, for any peak position, P using equation 7.2.3. 
 
 
  
   
  
 
   
 
 Equation 7.2.3 Calculating the scattering angle, θ΄.  
 
The scattering angle θ΄ can now be put back into Bragg’s law (equation 7.2.1) and the d-spacing 
calculated.  
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7.3 Results  
 
Tables 7.3.1 and 7.3.2 show the characteristic diffraction patterns observed for each of the seven 
phase/phase combinations observed.  The diffraction rings used to identify the phase have been 
labelled.  
Table 7.3.1 shows a SAXS image of a sample where no phase has been observed; this sample is 
thought to be in the micellar phase (L1) as this causes no diffraction rings and contains a very high 
percentage of LPC, which is known to self assemble into micelles108. Table 7.3.1 also shows a sample 
which is in the fluid lamellar phase (Lα), the gyroid inverse bicontinuous cubic phase (QII
G) and these 
two phases coexisting.  
Table 7.3.2 shows the inverse hexagonal phase (HII), the HII phase coexisting with the primitive 
inverse bicontinuous cubic phase (QII
P) and the HII phase coexisting with the QII
P
 and the double 
diamond inverse bicontinuous cubic phase (QII
D).  
  
73 
 
Table 7.3.1 Representative diffraction patterns of the different phases observed and the composition of each. The 
diffraction rings used to identify the phase have been labelled. T = 37°C. 
Composition / mol% Indexing Image Phase/s D-spacing / Å 
5% DOPC, 95% LPC 
 
L1  
15%DOPC, 75%LPC, 
10%OA 
 
Lα 76 
25%DOPC, 25%LPC, 
50%OA 
 
Lα + QII
G Lα = 72 
QII
G
 = 293 
20%DOPC, 30%LPC,  
50% OA 
 
QII
G 319 
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7.3.3 LPC and OA Mixtures, Path C 
 
Samples with no DOPC present have not been investigated in this study; however, samples with a 
fixed percentage of 5 mol% DOPC were examined. Figure 7.3.7 shows a graph of d-spacing versus 
percentage of OA for these samples. 
The L1 phase is observed at high percentages of LPC (95 mol%). The Lα phase (shown in purple in 
figure 7.3.7) is observed at intermediate LPC and OA concentrations (10-50 mol% OA), the Lα 
coexisting with a highly swollen (d-spacing = 271Å) QII
G phase at 35 mol% LPC and 60 mol% OA 
followed by the HII phase coexisting with a highly swollen (d-spacing = 246Å) QII
P at 30 mol% LPC 
and 65 mol% OA. The swollen cubic phases are shown in orange in figure 7.3.7. At high OA 
concentrations (20 mol% LPC and 75 mol% OA) the HII phase is observed. The HII phase is shown in 
blue in figure 7.3.7. SAXS images of the swollen cubic phases are shown in figure 7.3.8.  
The Lα d-spacing increases as the proportion of OA increases and the proportion of LPC decreases. As 
was seen in section 7.3.1 in samples that contain a high proportion of LPC some of the LPC will have 
budded from the bilayer forming micelles and so will not have a great affect on the d-spacing at these 
higher values. The increase in the amount of OA in the bilayer will cause the d-spacing to increase as 
observed in section 7.3.2. The Lα d-spacing increases up until 50 mol% OA. At 60 mol% OA a Lα 
phase with a reduced d-spacing is observed in coexistence with the swollen QII
G phase. This decrease 
in the Lα d-spacing occurs as a large proportion of the OA will now reside in the highly curved cubic 
phase. The addition of more OA causes the sample to adopt an even more highly curved set of phases, 
the HII and the QII
P. Finally the sample contains such a high amount of OA that only the highly curved 
HII phase exists.  
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It can be seen in the composition diagram in figure 7.3.10 that as the percentage OA is increased for a 
fixed percentage of DOPC several different phases are observed with higher (more negative) 
curvature. It is known that on going from a lamellar phase (zero curvature) to an inverse hexagonal 
phase (large negative curvature) a cubic phase will be observed in the intermediate region of 
membrane curvature2. 
If the inverse phases formed by the lipids are treated as the close packings of idealised inverse circular 
cylinders or inverse spheres then a void volume is created. This void volume has to be filled, the lipid 
hydrocarbon chains must stretch or compress away from their preferred conformation to compensate 
and fill these voids which has a large energy penalty1. The energy related to this packing is known as 
the packing frustration1.  
It has been found that the HII phase has a much higher packing cost than any of the three inverse 
bicontinuous cubics113, 116.  A detailed study of the effect of additions of an alkane to the 
monoacylglyceride 1-monoolein117 has shown that, under certain conditions, the system goes through 
a series of phase changes, each with increasing negative curvature. One of the changes was QII → HII. 
It was concluded that the relief of packing frustration by the alkane, by insertion into the packing 
voids, allowed the formation of phases with increasingly inverse interfacial curvature117. 
The addition of OA to the DOPC:LPC system also relieves this packing frustration allowing the 
phases with higher packing frustrations to exist at higher percentages of OA.  
There is a universal sequence in which the various possible phases occur, determined by the average 
mean curvature of the polar-nonpolar interface1, 31, this sequence is shown in figure 7.3.11. Not all 
three of the bicontinuous cubic phases necessarily occur for a given phospholipid system1. As the 
mole fraction of fatty acid is increased in a fatty acid/phospholipid system one would expect the 
phases observed to occur in the “natural” sequence.  
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The more highly curved phases are observed with increasing additions of FA because the FA 
molecules make a significant difference to the structural forces which destabilize the flat lamellar 
phase and give rise to phases with interfacial curvature18.  
It has been suggested that there is direct hydrogen bonding between the carboxylic acid in the FA and 
phosphate moieties18, 120 in the phospholipid, with the FA head groups lying close to the glycerol 
backbone of the phosphatidylcholine molecule. In 2:1 FA:PL systems studies18 it is suggested that the 
cross-sectional area around the PC bound by two FA molecules is greater than is required for full head 
group hydration of the PC on its own. At the same time the lateral pressure in the chain region must 
have increased since the average area per chain has decreased upon addition of FA molecules. This 
lateral pressure drives the interface to bend toward the aqueous phase. The excess cross-sectional area 
around the PC means that the interface can maintain high degrees of monolayer curvature before they 
begin to experience strong steric repulsions from their neighbouring PC molecules. The bilayer’s 
desire for negative mean interfacial curvature arises because of the differential lateral pressures which 
are present; the transition from Lα → QII → HII relieves the packing frustration caused by the addition 
of OA.  
A mixture of phases is observed in some samples because lipids in mixed systems tend to segregate, 
adjusting their composition to simultaneously minimise bending and hydrocarbon packing energies121.  
One sequence of phases that occurs in the composition diagram when the proportion of OA is 
increased by 5 mol% with each step and at fixed amounts of DOPC (10 mol% DOPC) is the Lα (103 
Å) → QII
G (271 Å) + Lα (71 Å) → QII
P (246 Å) + HII (79 Å) → HII (62 Å). Increasing additions of OA 
favour the QII
G
 + Lα phases over the Lα phase. A significant proportion of the OA will now reside in 
the cubic phase, relieving the lateral pressure in the chain regions caused by the OA in the Lα phase. 
At even higher OA proportions the QII
P + HII phases coexist. The QII
P
 phase has a lower curvature than 
the QII
G
 phase so one would expect it to be observed at lower proportion of OA as has been seen 
previously. In this transition the total amount of curvature has increased and the result shows that the 
formation of two separate phases QII
P + HII one with intermediate curvature and one that is very highly 
curved is more favourable than formation of the two separate phases QII
G + Lα one of which has zero 
curvature and one that has high curvature.  
Another sequence of phases is observed at a fixed amount of DOPC (40 mol%). On increasing the 
proportion of OA by 5 mol% with each step the sequence of phases appear are Lα (101 Å) → QII
P 
(204 Å) + HII (64 Å) → QII
P (215 Å) + QII
D
 (176 Å) + HII (66 Å) → HII (63 Å).  The same sequence of 
phases is also observed at 30 mol% DOPC. The same phases are observed at 20 mol% DOPC but the 
sequence in which they appear is different. On increasing the proportion of OA by 5 mol% with each 
step the sequence of phases appear are QII
P (234 Å) + QII
D
 (181 Å) + HII (65 Å) → QII
P (197 Å) + HII 
(65 Å) → HII (58 Å).  One explanation for this is that for samples with 40 mol% DOPC and 30 mol% 
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DOPC the total amount of curvature of the QII
P + QII
D
 + HII phases must be higher than the QII
P + HII 
phases and for the samples with 20 mol% DOPC the reverse must be true. Another possible 
explanation is that the second sequence of phases (20 mol% DOPC) is incorrect due to a sample error 
as this sequence occurs only once in the composition diagram and the first sequence of phases (40 
mol% DOPC and 30 mol% DOPC) is correct as this sequence of phases appears twice.  
Previous work has shown that in 2:1 LA:DLPC systems that the size order of the d-spacing for the 
inverse bicontinuous cubic phases follows the order QII
D < QII
P < QII
G at a fixed temperature and 
hydration18, this is in agreement with was has been observed in this work. The d-spacings measured in 
this work are much larger than the d-spacings reported in this previous work; however, in the previous 
work these were measured at lower hydrations and the authors predict larger d-spacings at higher 
hydrations.   
Monoelaidin in excess water has been reported to have a Lα phase coexisting with a QII
D phase with a 
d-spacing of 232 Å and a lamellar gel phase coexisting with a QII
P phase with a d-spacing of 311 Å; 
however, these swollen phases were observed using pressure jumps122. As far as can be ascertained, 
the swollen cubic phases observed in this work have the largest d-spacings recorded for lipid samples 
at atmospheric pressure.  
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7.4 Comparison with Cryo-TEM Results 
 
The phase behaviour of PL/LPC17 systems and of PL/FA18 systems  have been investigated 
previously; however, few studies have been made on systems containing all three components. 
However, one study that did used cryo-transmission electron microscopy (cryo-TEM)114 to investigate 
the structures formed by liposomes made of varying quantities of  egg-phosphastidylcholine (DOPC), 
LPC  and OA.  
In the cryo-TEM study liposomes, disk-like structures, thread-like cylindrical micelles, dispersed 
particles of inverse structures and large invaginated unilamellar liposomes were observed. Cryo-TEM 
revealed that the pure DOPC sample consisted of unilamellar liposomes with no structural changes 
observed after 14 days of incubation at 25°C. This result is consistent with the observation that pure 
DOPC in the condensed phase forms a lamellar structure.  
At high concentrations of OA the two sets of results correlate. The authors of the cryo-TEM paper114 
have observed sponge-like structures, which they speculate to be cubic phases in the same region of 
the composition diagram as inverse bicontinuous cubic phases have been observed. At higher 
concentrations of OA they have observed dense particles of inverted structures, which they speculate 
to be the inverse hexagonal phase (figure 7.4.1) in the same region of the composition diagram that 
the inverse hexagonal phase has been observed.  
 
 
Figure 7.4.1 Structures formed in the OA/DOPC system, dispersed by vortexing, at 25°C. OA:DOPC 4:1. Note the non-
lamellar structures (marked with an arrow). Bar = 100 nm114.  
 
 
 
90 
 
The structures observed at equimolar amounts of OA and LPC in both studies are of interest to those 
studying the CAD-catalysed or enzyme-mediated hydrolysis of phospholipids. The composition 
diagram produced shows that in the condensed phase at equimolar amounts of these degradation 
products only the Lα phase is observed. As the proportion of OA and LPC is increased the d-spacing 
of the lamellar phase increases, as shown in figure 7.3.9.  
The cryo-TM paper114 shows that small and equimolar amounts of OA and LPC formed at the early 
stages of the hydrolysis process would have little effect on the aggregate structure formed. In both 
cases quite extensive hydrolysis would be needed before any gross structural changes could be 
detected.  
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7.5 Hydrolysis Map 
 
One of the aims of investigating the phase behaviour of a lipid system which consisted of DOPC and 
the degradation products of DOPC hydrolysis by a CAD, namely OA and LPC, was to monitor the 
extent of hydrolysis of a DOPC:CAD sample. The phase and d-spacing of a DOPC:CAD sample can 
be monitored over time using SAXS; from this knowledge the composition diagram can be used to 
deduce the DOPC:LPC:OA composition of the sample and hence the extent of DOPC hydrolysis.  
In the composition diagram produced it can be seen that only samples containing 60 mol% of DOPC 
or less exhibit phases other than the Lα phase and that all samples containing more DOPC than this are 
all in the Lα phase. This shows that significant hydrolysis (≥ 40 mol% DOPC hydrolysed) would have 
to occur before a phase change would be observed.  
The composition diagram also shows that pure DOPC has a Lα d-spacing of 62 Å, a sample containing 
90 mol% DOPC and 10 mol% LPC, and a sample containing 90 mol% DOPC and 10 mol% OA both 
have Lα d-spacings of 65 Å. A sample containing 80 mol% DOPC, 10 mol% LPC, and 10 mol% OA 
has a d-spacing of 67 Å. Using this information it can be deduced that only 10 mol% of DOPC needs 
to be hydrolysed before a detectable change in the Lα d-spacing can be observed.  
 
7.6 Chapter Summary 
 
The composition diagram produced is comparable to the phases observed in previous work1. Over a 
wide range of temperatures, DOPC mixed with water will form a fluid lamellar structure (Lα), 
mixtures with a large proportion of LPC form micellar aggregates with an interface that curves 
strongly away from the aqueous interface and DOPC:LPC:OA mixtures with a high proportion of OA 
exhibit a strong propensity for interfacial curvature toward the water, forming inverse bicontinuous 
cubic phases (QII) and the inverse hexagonal phase (HII) when sufficient OA is present.  
The composition diagram has revealed the presence of many inverse bicontinuous cubic phases and 
combinations of these phases with the Lα and HII phase that has not been seen in this system before. 
The presence of such highly swollen cubic phases has not been observed previously at atmospheric 
pressure (as far as can be ascertained) but has been predicted by swelling models18.  
  
92 
 
8 Biophysical Results 
8.1 Introduction 
 
These experiments were performed to explore the influence of drug structure on the extent of 
membrane hydrolysis (described in section 5.2.2.2) and on membrane interaction.   
This was achieved by making a series of biophysical measurements of the Spiperone analogues 
(described in chapter 6) interaction with multilamellar vesicles using SAXS (described in section 
7.1.1) and HPLC (described bellow in section 8.1.1.). The lipophilicity of the Spiperone analogues 
and their interaction with an immobilised membrane were also measured using HPLC (described 
below in section 8.1.2).  
 
8.1.1 HPLC of Lipid Mixtures 
 
HPLC is a much more sensitive technique than SAXS to measure lipid hydrolysis as it gives an 
accurate and reproducible breakdown of the components of lipid mixtures. It is used to quantify the 
amounts of LPC formed in a DOPC:CAD sample over time and so the rate and extent of DOPC 
hydrolysis. However, the technique provides no information about the phase or mesostructure of the 
systems under analysis, so the two techniques can be used together to analyse drug-lipid samples.  
 
 
Figure 8.1.1 A schematic of the detection chamber of an ELSD device123.  
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In the HPLC system used to study lipid hydrolysis by CADs, an evaporative light scattering detector 
(ELSD) shown in the schematic above (figure 8.1.1), is linked to an HPLC column in reverse phase. 
This detector can quantitatively analyse the components of any sample in which the solvent is more 
volatile than the analyte. The ELSD response is dependent upon the particle size, shape and surface 
properties of any particle travelling through it so that a mixture of compounds will have different 
intensities even when present in the same concentration. The response from a given compound is 
linear with its concentration expect for at very low concentrations. Calibration is performed by 
comparing results to concentration/response plots of reference standards.  
 
8.1.2 HPLC to Measure Lipophilicity 
 
HPLC is also used to measure the lipophilicity of drugs. The parameter measured is called the 
chromatographic hydrophibicity index (CHI). CHI utilizes the retention times of drugs on various 
types of columns72 from a rapid gradient reversed phase elution to measure lipophilicity. Calibration 
is performed by comparing retention times with literature-accepted standards with known CHI values. 
The CHI lipophilicity scale differs from the octanol/water lipophilicty scale, it has been shown that 
the CHI lipophilicity is more similar to a water/alkane type of partition in that it is sensitive to H-bond 
acidity of the compounds whereas the octanol/water partition is not73.  
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8.2 Materials and Methods 
8.2.1 Samples 
 
The phospholipid DOPC (structure shown in table 7.2.1) was purchased from Avanti Polar Lipids, Inc 
Birmingham, AL.  
Buffer A consisted of 50mM bis-tris and 100mM NaCl at pH 7.4 and was made using 18.2 MΩ Milli-
Q water and its pH was adjusted to 7.4 using a Hanna Instruments (Leighton Buzzard, UK) pH210 
Microprocessor digital pH meter. The chemicals used to make the buffer were purchased from 
Aldrich Chemical Co. (Gillingham, UK). 
All commercial materials used were of the highest purity available (>99%) and were subsequently 
used without further purification.  
 
8.2.1.1 DOPC:CAD Samples for SAXS  
 
Stock solutions of DOPC and a single CAD were made in methanol and/or chloroform. The samples 
were then dried under a nitrogen stream and lyophilised. Once fully dried, Milli-Q water or buffer was 
added by micropipette to each to make up samples of 2/3 water or buffer by mass and labelled 
according to table 8.2.1. The vials were then vortexed and centrifuged to ensure homogeneity in the 
sample and then made up as described in section 7.2.1. The samples were incubated at 37°C 
throughout the course of the experiments in aluminium heating blocks. SAXS images of the 
DOPC:CAD samples were recorded over time and analysed as described in section 7.2.3.  
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Table 8.2.1 List of name codes and relevant mixture compositions.  
CAD Sample Name Hydration % mol CAD 
SpipC0me C010W Water 10 
SpipC0me C010B Buffer A 10 
SpipC2me C210W Water 10 
SpipC2me C210B Buffer A 10 
SpipC3me C310W Water 10 
SpipC3me C310B Buffer A 10 
SpipC4me C410W Water 10 
SpipC4me C410B Buffer A 10 
SpipC6me C610W Water 10 
SpipC6me C610B Buffer A 10 
 
 
8.2.1.2 DOPC:CAD Samples for HPLC 
 
The DOPC:CAD samples tested to measure the rates of lipid hydrolysis using HPLC were made in 
the same way as described in section 8.2.1.1 and hydrated with buffer A. The samples were incubated 
at 37°C throughout the course of the experiments in aluminium heating blocks.  Six µl of the sample 
were taken every 3-4 days and placed in an HPLC vial. The sample was then lyophilised to remove 
the buffer and 1ml of methanol added before loading into the HPLC autosampler.  
 
8.2.1.3 CAD Samples for Lipophilicity Measurements 
 
Each CAD used was dissolved in DMSO at a concentration of 10mM. The 10mM DMSO solutions 
were then diluted down to 0.5mM CAD with a mixture of 50% pH 7.4 ammonium acetate buffer and 
50% 2-propanol to ensure maximum dissolution. 5µl aliquots of the solutions were then injected onto 
the HPLC column.  
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8.2.2 HPLC Conditions 
8.2.2.1 Lipid Hydrolysis 
 
The HPLC conditions used were conducted using Waters 626 HPLC pump, via a 150 x 3.9 mm 
Symmetry Shield C8 reverse phase column,  donated by Pfizer PLC, (Sandwich, UK)  and analysed by 
evaporative light scattering, using an ESA 301 detector, (baseline noise +/- 0.4%, evaporation 
temperature 80°C, drift tube 45°C). The mobile phase ran from 0.1% formic acid (solvent A) to 
methanol  (solvent B) over a 18 minute gradient, with 5 minutes of pure solvent A after each analysis 
to allow full equilibration.  
 
Calibration factors of DOPC and lyso-PC were provided by Duncan Casey124. Fatty acid signals were 
not calibrated due to issues with reproducibility and resolving them from the solvent injection front. 
 
8.2.2.2 Lipophilicity Measurements 
 
CHI_Log D values were measured at three pHs (pH 2.2, pH 7.4, pH 10.5) using a Luna C-18(2) 
HPLC column (Chromtech, Cheshire, U.K.) with dimensions of 50 x 3mm. The mobile phase A was a 
50 mM ammonium acetate solution at either pH 7.4 or 10.5, or a 0.01M phosphoric acid solution at 
pH 2.2. The mobile phase B was acetonitrile.  The mobile phase flow rate was 1.0 ml/min and the 
column temperature kept at 30°C. The linear gradient of 0 to 100% acetonitrile was applied from 0 to 
2.5 min. From 2.5 to 3.0 min the mobile phase composition was at a constant 100% acetonitrile and 
0% mobile phase A. From 3 to 3.2 min the mobile phase composition was changed to 100% mobile 
phase A only until the end of the run. The separation was stopped after 4 min. Chromatograms were 
recorded at 230 and 254 nm by a diode array UV absorption detector at room temperature. Agilent 
HP1100 HPLC instruments were used throughout. 
 
The retention time of a compound on the Log D column was recorded and using calibration data from 
compounds with known Log D values, the chromatographic hydrophobicity index, CHI, was 
calculated.  The values were then converted to CHI_Log Dx using equation 8.2.1.  
 
                          
 
Equation 8.2.1 Calculating CHI Log D values71, x is equal to the pH of the mobile phase used.  
 
97 
 
CHI_IAM values were measured using an IAM PC2 (CH2)12 12 Micron 300 HPLC column 
(Chromtech, Cheshire, UK) with dimensions of 150 x 4.6 mm. The mobile phase A was 50 mM 
ammonium acetate solution at pH 7.4 and mobile phase B was acetonitrile. The mobile phase flow 
rate was 2.0 ml/min. The column temperature was kept at 30°C. The linear gradient for 0 to 70% 
acetonitrile was applied from 0 to 2.5 min. From 2.5 to 3.0 min the mobile phase composition was 
constant 70% acetonitrile and 30% mobile phase A. From 3 to 3.3 min the mobile phase composition 
was changed to 100% mobile phase A only until the end of the run. The separation was stopped after 
4 min. Chromatograms were recorded at 230 and 254 nm by a diode array UV absorption detector at 
room temperature. Agilent HP1100 HPLC instruments were used throughout. 
 
The retention time of each CAD on the IAM column was recorded and using calibration data from 
compounds with known CHI_IAM values125, the CHI_IAM  for each compound was calculated.  
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8.3 Results  
8.3.1 SAXS of DOPC:CAD Samples 
 
Table 8.3.1 shows the phase and d-spacing observed for each sample at a given time after water or 
buffer was added to the sample (as described in section 8.2.1.1). All the samples are in excess water. 
Unfortunately, images were only acquired from day 5 onwards due to beamline downtime.  The 
results for the CAD SpipC2me are in a separate table, table 8.3.2 for simplicity.         
 
Table 8.3.1 The Lα d-spacing observed in CAD-DOPC samples. Lα d-spacing in Å. * = unable to identify phase, / = no 
phase observed. An empty cell indicates that no image was taken on that day. Sample names ending in W and B indicate that 
water or buffer was added, respectively.  
Drug Sample Name Sample set Day 5 Day 6 Day 11 Day 13 Day 18 
SpipC0me C010W A 61.1 
 
61.2 61.3 60.9 
 C010W B / 60.9 58.5 59.8 58.5 
 C010B B 64.0 63.8 64.0 62.5 63.2 
SpipC3me C310W A 62.5 
 
61.7 61.3 61.8 
 C310W B / / / / 63.4 
 C310B B 61.0 63.0 62.9 62.4 63.3 
SpipC4me C410W A 67.9 
 
68.4 64.0 67.2 
 C410W B / / / / 62.7 
 C410B B / 63.1 63.3 / 62.4 
SpipC6me C610W A 52.0 
 
* / * 
 C610W B 62.8 / / 63.8 62.6 
 C610B B / 64.0 62.8 61.6 61.7 
 
 
As can be seen in the above table, there was little change in the Lα d-spacing for SpipC0me:DOPC 
sample over time. If a protonated drug is bound to the membrane interface this promotes the 
formation of a swollen fluid lamellar Lα phase, the swelling being due to the repulsion between the 
two charged bilayers126. The lack of swelling observed in the SpipC0me:DOPC sample could be due 
to the CAD not binding to the membrane interface or not binding in its protonated state. Figure 8.3.1 
shows SAXS images of a  SpipC0me:DOPC sample hydrated in Milli-Q after 5 and 18 days.  
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previously with cationic polyelectrolytes and drugs possessing acidic groups129 and with acidic 
polyelectrolytes and basic drugs130. 
 
The large d-spacings observed are similar to those of DOPC:LPC:OA samples (discussed in section 
7.3.4) with a large proportion of LPC and OA (103.47 Å for a sample with 5 mol% DOPC, 45 mol% 
LPC and 50 mol% OA). However, the SpipC2me sample (set C) was analysed on day 15 using HPLC 
(and not after due to lack of sample). The sample contained 2.7% of LPC and had a d-spacing of 75.2 
Å. This result confirms that the increase in d-spacing (relative to pure DOPC) is not due to the 
presence of large amounts of LPC and OA caused by the extensive hydrolysis of the DOPC.  
 
Precipitation of the CAD from the bilayer would halt the DOPC hydrolysis reaction and the mol% 
LPC in the sample would plateau. Future experiments would be to analyse SpipC2me:DOPC samples 
using  SAXS and HPLC in parallel; however, this was not done due to time constraints. 
SpipC2me:DOPC samples have been analysed over time (see section 8.3.2) using HPLC; however, no 
LPC was observed in these cases. 
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8.3.2 Lipid Hydrolysis Assay 
 
Aliquots of DOPC:CAD samples were analysed over time using HPLC as described in sections 
8.2.1.2 and 8.2.2.1. Only one of the two samples of SpipC0me analysed had a peak present in the 
characteristic retention time of LPC; an HPLC trace of this is shown in figure 8.3.6 a.   However, the 
intensity of the peak did not increase over time, as shown in table 8.3.3. The LPC peak is present at 
time point 0 hours, 170 hours, and 409 hours; however, this peak is not present in the time points in 
between or after 409 hours. A possible explanation for the LPC peak area reducing over time is that 
SpipC0me has a higher affinity for hydrolysing LPC than for hydrolysing DOPC. Once the LPC 
concentration is high enough the drug starts to hydrolyse this in preference to the DOPC and the 
amount of LPC decreases below detectable levels. As LPC is hydrolysed OA is formed, which cannot 
be observed in the HPLC system used. The appearance, disappearance and reappearance of the LPC 
peak is shown in figure 8.3.6 b. Figure 8.3.6 a shows the HPLC trace with the DOPC peaks at ~10.5 
minutes and the LPC peaks at ~6.5 minutes highlighted with the red box and figure 8.3.6 b shows the 
LPC region expanded. The LPC peak is present at t = 000 hours and t = 170 hours but at time point t = 
074 hours between these two it is indistinguishable from background noise.  
 
Another explanation could be that the small peaks (≤ 1 % LPC) observed are due to experimental 
noise not due to LPC being formed. In the second SpipC0me:DOPC sample tested no LPC was 
observed.  
 
 
a) b) 
  
Figure 8.3.6 HPLC traces for the SpipC0me:DOPC mixture (sample 1).  a) The normalised HPLC trace, the red box 
highlights the peak due to LPC. b) The HPLC trace at higher magnification.  
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Table 8.3.3 Shows the mol% of LPC in DOPC:CAD samples over time for the drug SpipC0me.  
Incubation 
Time / hours 
t = 0 t = 74 t = 170 t = 241 t = 337 t = 409 t = 502 
Mol % LPC 
(sample #1) 
0.9 0.0 1.0 0.0 0.0 0.8 0.0 
Mol % LPC 
(sample #2) 
0.0 0.0 0.0 0.0 0.0 0.0 0.0 
 
The two samples of SpipC2me:DOPC that were made for HPLC analysis showed that no hydrolysis 
had occurred; however, as discussed previously in section 8.3.1 the SpipC2me sample made for 
SAXS analysis showed that hydrolysis had occurred as the sample contained 2.7 % LPC.  
 
Both of the SpipC3me:DOPC samples showed a small level of LPC present after 337 hours; however, 
the peak size reduced over time, this was seen in both samples. Figure 8.3.7 a shows the HPLC trace 
with the DOPC peaks at ~10.5 minutes and the LPC peak at ~6.5 minutes highlighted with the red 
box. Figure 8.3.7 b shows the LPC region expanded. The size of the LPC peak decreases from 2.6 % 
at t = 337 hours to < 0.5% LPC at t = 409 hours.   
 
The explanation for this could be again that SpipC3me has a higher affinity for hydrolysing LPC over 
DOPC so as the LPC is formed it is hydrolysed by the CAD forming OA and a PC head group, neither 
of which are detectable in this HPLC system. The extent of hydrolysis in both SpipC3me:DOPC 
samples is shown in table 8.3.4.  
 
a) b) 
  
Figure 8.3.7 HPLC traces for the SpipC3me:DOPC mixture (sample 2).  a) The normalised HPLC trace, the red box 
indicates the peak due to LPC. b) The HPLC trace at higher magnification.  
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Table 8.3.4 Shows the mol% of LPC in DOPC:CAD samples over time for the drug SpipC3me. The / indicates that the 
data was too noisy to analyse and the * indicates that a LPC was observed but was too small to accurately quantify.  
Incubation 
Time / hours 
t = 0 t = 74 t = 170 t = 241 t = 337 t = 409 t = 502 
Mol % LPC 
(sample #1) 
0.0 0.0 0.0 0.0 1.9 1.0 * 
Mol % LPC 
(sample #2) 
0.0 0.0 0.0 0.0 2.6 * / 
 
Neither of the SpipC4me:DOPC and SpipC6me:DOPC samples showed any sign of degradation.   
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8.3.3 Lipophilicity Measurements 
 
For each CAD the CHI_ Log D at various pHs and the CHI_IAM was measured three times and the 
average recorded as the Log D or CHI_IAM for the molecules. Small errors between each experiment 
indicated that the reproducibility of the HPLC assay is very high and the results are accurate. All 
values are quoted as a chromatographic hydrophobicity index, CHI, value. 
 
8.3.3.1 Log D 
 
Figure 8.3.8 shows the Log D data acquired. It was expected that as the length of the carbon chain is 
increased the lipophilicity would increase. The measured lipophilicity of SpipC0me at pH 2.2 is much 
larger than that of the other CADs. The basicity of the nitrogen atom in the six membered ring in the 
SpipC0me molecule is much lower than that of the other CADs as it is an amide nitrogen rather than 
an amine nitrogen. Because of this a higher proportion of the SpipC0me molecules will be in the 
neutral form compared to the other analogues so it will have a much greater affinity for the aliphatic 
chains of the column (stationary phase) than the other CADs. A higher proportion of the other CADs 
will be in the protonated form at this pH and so have a much lower Log D at this pH than SpipC0me.  
 
At pH 10.5 there is a general increase in lipophilicity with increasing carbon chain length as all of the 
CADs will be in the neutral form and have an affinity for the stationary phase. This hydrophobic 
interaction will increase with increasing carbon chain length so the CAD with the largest alkyl chain, 
SpipC6me, will have a higher Log D at this pH than the smaller CADs.  
 
The lipophilicity of the CADs at pH 7.4, physiological pH, shows no observed trend between 
molecular size and affinity for the column.  
 
The Log D of SpipC0me at all three pHs is very similar indicating that the protonation state of this 
molecule does not alter as much as the other CADs across this pH range. This implies that the 
nitrogen atom in the six membered ring is protonated at low pHs for the other four CADs as this 
amine group is more basic than the amide nitrogen atom in the six membered ring in the SpipC0me 
molecule.  
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Figure 8.3.8 A graph of Log D versus molecular weight. The experiment was performed three times and the average 
plotted. Error bars are equal to two standard deviations.  
8.3.3.2 CHI_IAM 
 
Figure 8.3.9 shows that as the molecular weight of the Spiperone analogue increases so does the 
CHI_IAM value.  As the length of the central carbon chain is increased so does the hydrophobic 
interaction of the CAD with the immobilized artificial membrane (IAM), shown in figure 8.3.10. The 
CHI_IAM value for SpipC0me is significantly lower than for the other CADs because the central 
carbon chain is absent in this molecule and so the hydrophobic interaction with the PC group much 
lower. Another reason for the much lower interaction of the SpipC0me molecule with the IAM could 
be due to the fact that the nitrogen atom in the 6 membered ring is an amide nitrogen rather than an 
amine nitrogen as in the other CADs. A higher proportion of the amine group containing CADs will 
be protonated than the amide containing SpipC0me because the amine group is more basic than the 
amide. This will lead to an increased interaction of the positively charged CADs with the negatively 
charged phosphate groups or the glycerol back bone of the IAM shown in figure 8.3.10.  
These results are not in agreement with what has been observed in the SAXS experiments in section 
8.3.1 where SpipC2me had the largest interaction with DOPC.  
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8.4 Comparison with Composition Diagram 
 
The composition diagram in section 7 and the graph in figure 7.3.9 were constructed to determine the 
composition of mixtures of DOPC, LPC and OA by measuring their d-spacing. Table 8.4.1 shows the 
maximum d-spacing of DOPC:CAD samples measured in section 8.3.1. Table 8.4.1 also shows the 
composition of these samples calculated using graph 7.3.9; the mol% of DOPC was determined by 
interpolation and the mol% of LPC calculated by assuming that for every mol of DOPC hydrolysed 
one mol of LPC and one mol of OA is produced. The composition of DOPC:CAD samples measured 
in section 8.3.2 using HPLC are also included in the table.  
 
Table 8.4.1 The d-spacing, calculated compositions, and measured compositions of DOPC:CAD samples. The d-
spacing and composition were measured using different samples, except for SpipC2me where the same samples was 
analysed.  
CAD Maximum d-
spacing / Å 
Calculated 
DOPC / mol% 
Calculated  
LPC / mol% 
Measured  
LPC / mol% 
SpipC0me 64 95 2.5 1.0 
SpipC2me 110 5 47.5 2.7 
SpipC3me 64 95 2.5 2.6 
SpipC4me 68 80 10.0 0.0 
SpipC6me 64 95 2.5 0.0 
 
 
The results in table 8.4.1 show that the composition diagram constructed is not suitable for measuring 
the extent of DOPC hydrolysis by CADs because the increase in d-spacing is not due to significant 
amounts of LPC being generated. As discussed in section 8.3.1 an increase in d-spacing is observed 
because the presence of a protonated drug at the membrane interface promotes the formation of a 
swollen fluid lamellar Lα phase, the swelling being due to the repulsion between the two charged 
bilayers126; the composition diagram does not take this effect into account. The addition of an 
amphilipic cationic species such as dimethylditetradecylammonium bromide into the DOPC:LPC:OA 
mixtures would mimic the CAD due to its charge but would not initiate DOPC hydrolysis. This would 
allow the impact of the CADs charge to be modelled but would not account for the varying 
proportions of CAD entering the bilayer, exhibited by the variation in d-spacings of DOPC:CAD 
samples observed.  
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8.5 Chapter Summary 
 
In this chapter the effect that Spiperone analogues have on multilamellar vesicles (MLVs) was 
investigated using SAXS and HPLC. In SAXS experiments, the CAD SpipC2me was shown to have 
the highest aggregation in the MLVs and in HPLC experiments was shown to hydrolyse DOPC.  
In this chapter it was also shown that the composition diagram constructed in chapter 7 is not suitable 
for measuring the extent of DOPC hydrolysis by CADs.  
The interaction of the Spiperone analogues with an immobilised artificial membrane (IAM) was 
measured using HPLC. CADs with the longest central carbon chain were shown to have a larger 
interaction with the membrane and the CAD SpipC0me, which has no central carbon chain, had a 
significantly smaller interaction. This implies that the interaction with the IAM is dominated by a 
hydrophobic interaction between the lipid chains and the central carbon chain in the CAD molecule.  
  
113 
 
9 Calcein Leakage Assay 
9.1 Introduction 
 
A Calcein leakage assay has been used to measure the interaction of the Spiperone analogues 
discussed in section 6.1.2 with DOPC unilamellar vesicles. Using unilamellar vesicles instead of lipid 
in the bulk phase will more closely mimic the drug’s interaction with a cell membrane.   
This assay was based on the self-quenching properties of the fluorescent dye Calcein131-134. At very 
low concentrations the fluorescence intensity of a Calcein solution is low, as the concentration 
increases so does the fluorescence intensity up to a maximum value. At concentrations higher than 
this the fluorescence intensity decreases as the Calcein molecules self quench. In this work, vesicles 
were made that contained a high concentration of Calcein; when these vesicles were disrupted by 
CAD molecules some of the Calcein leaks out into the surrounding solution, the concentration of 
Calcein is reduced and an increase in fluorescence intensity is observed. The rate of this leakage can 
be measured and hence the strength of the CADs interaction with the DOPC bilayer. This method has 
been shown schematically in figure 9.1.1.  
 
 
Figure 9.1.1 A schematic of Calcein leaking from DOPC vesicles. Ex/Em = 490/520nm. Initially the DOPC vesicle 
contains Calcein that is self quenching, shown by orange shading. After addition of CAD (shown in red) solution the Calcein 
begins to leak out of the vesicle, shown in yellow, causing the fluorescence intensity to increase. Finally the vesicle is 
ruptured with the detergent, C12E8, and all of the Calcein leaks into the surrounding solution. 
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9.2 Materials and Methods  
9.2.1 Vesicle Preparation  
 
The lipids DOPC and 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(lissamine rhodamine B 
sulfonyl) ammonium salt (Rhodamine PE) were purchased from Avanti Polar Lipids, Inc 
Birmingham, AL. 
The buffers used in this chapter are detailed in table 9.2.1. Buffers B-D were made up using 18.2 MΩ 
Milli-Q water and their pHs were adjusted to 7.4 using a Hanna Instruments (Leighton Buzzard, UK) 
pH210 Microprocessor digital pH meter. The chemicals used to make the buffer were purchased from 
Aldrich Chemical Co. (Gillingham, UK). 
All commercial materials used were of the highest purity available (>99%) and were subsequently 
used without further purification.  
 
 
Table 9.2.1 The compositions of buffers used in this work.  
Buffer Composition 
B 20mM HEPES, 100mM KCl, pH 7.4 
C 20mM HEPES, 100mM KCl, 50mM Calcein, pH 7.4 
D 20mM HEPES, 100mM KCl, 500mM Sucrose, pH 7.4 
 
 
DOPC multi-lamellar vesicles were formed by drying a DOPC-chloroform solution under a nitrogen 
stream and lyophilising for a minimum of twelve hours. Once fully dried, buffer was added by 
micropipette to make the DOPC concentration 6.7mM and the sample was then subjected to five 
freeze-thaw-vortex cycles to ensure homogeneity. The sample was loaded into a 1ml gas-tight syringe 
which was placed in one end of an Avanti Mini Extruder (figure 9.2.1) and an empty syringe placed in 
the other end. The sample was then extruded twenty one times through a 100nm polycarbonate 
membrane (Whatman) to create a suspension of Calcein-containing unilamellar vesicles.  
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9.2.2 Fluorimetry 
 
The fluorescence intensity of the vesicle solutions was measured by transferring the solution into a 
black quartz 96-well plate (Hellma) using a micropipette and placing the plate in a Varian Cary 
Eclipse Fluorimeter with reflected optics. 
For the control experiments 9.2.3.1, 9.2.3.2, and 9.2.3.5 the fluorescence intensity was measured in 
the scanning mode. Samples were excited at 490nm, the emission spectra recorded between 500 and 
550 nm (500 and 600 nm for 9.2.3.5) and the emission intensity value at 520 nm noted. The 
photomultiplier voltage was set to 500 V, the excitation/emission band slits set to 5/5 nm and the scan 
rate set to 600 nm/min.  
For control experiment 9.2.3.3 the fluorescence intensity was measured in the scanning mode. 
Samples were excited at 557 nm, the emission spectra recorded between 565 and 600 nm and the 
emission intensity value at 595 nm noted. The photomultiplier voltage was set to 500 V, the 
excitation/emission band slits set to 5/5 nm and the scan rate set to 600 nm/min. 
For control experiments 9.2.3.6 – 9.2.3.8 and experiment 9.2.4 the fluorescence intensity was 
monitored at 2 minute time intervals using the kinetics mode.  The samples were excited at 490 nm 
and the emission intensity at 520 nm plotted. The photomultiplier voltage was set to 500 V and the 
excitation/emission band slits set to 5/5 nm.  
The well plate temperature was kept at 37°C during all experiments using a heating matt (0.7 mm 
thick, RS) placed underneath the quartz plate inside the fluorimeter and connected to a  temperature 
control unit (E5CN-Q2MT-500 AC100-240, Omron). Also connected to the control unit was a Pt100 
sensor coated in water resistant thermally conducting glue (low corrosive thermally conductive 
adhesive sealant, AccSilicones, RS) and this was submerged into a well containing sample to test the 
temperature of  the samples within the plate. This equipment and set-up was designed by Natalia 
Goehring136.   
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9.2.3 Control Experiments 
 
A large number of calibrations and controls were undertaken to ensure that the measured increase in 
fluorescence intensity is due to the disruption of the DOPC bilayer by CADs and not due to any other 
interaction.  The quantities of vesicles and CADs that gave rise to meaningful results were also 
determined.  
 
9.2.3.1 Calcein Dye Characterisation 
 
As discussed in section 9.1 this assay is based on the self quenching properties of Calcein at high 
concentrations and the increased fluorescence below this concentration. Fluorescence measurements 
of Calcein in buffer were made to confirm its behaviour and ensure the correct concentration was 
being used.  
 
For the Calcein dye calibration experiment, Calcein was dissolved in buffer D to a concentration of 
100mM. This was then diluted down to varying concentrations and 200µl added to wells in the plate 
by micropipette and the fluorescence intensity measured. The calibration curve is shown in figure 
9.2.3.  
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Figure 9.2.3 A graph of fluorescence intensity versus the log of the Calcein concentration. The Calcein concentration 
was measured in M, the buffer used was buffer D, T = 37°C, Ex/Em = 490/520 nm. The experiment was performed three 
times and the average plotted. The error bars are equal to two standard deviations.  
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contain external Calcein. This external Calcein can also be observed by eye; fractions collected before 
this are faint orange in colour and the fractions collected after are intense yellow in colour.  
a) b) 
  
 
Figure 9.2.5 A graph of fluorescence intensity change versus fraction number. The fluorescence intensity was measured 
before and after addition of 1µl of 200mM C12E8. a) Calcein solution loaded onto the column b) vesicles extruded in Calcein 
solution loaded onto the column. Ex/Em = 490/520 nm, elution buffer was buffer D and T = 37°C. The experiment was 
performed three times and the average plotted. The error bars are equal to two standard deviations.  
 
9.2.3.3 Lipid Concentration  
 
To determine which eluted fraction contained the highest concentration of lipid, the fluorescent lipid 
Rhodamine PE was incorporated into DOPC vesicles.  
 
DOPC was mixed with 1% Rhodamine PE and dried under a nitrogen stream and lyophilised for a 
minimum of twelve hours. The mixture was then hydrated with buffer D and vesicles extruded as 
described in section 9.2.1. The suspension was diluted in buffer D to varying concentrations and 
200µl of each solution added to the well plate by micropipette. The fluorescence intensity values 
were then plotted against concentration, shown in figure 9.2.6 a.  
 
The data were fitted using Origin and a number of fits were tested. The best fit was equation 9.2.1 
below which had an r2 value of 0.98.  
 
     
(
 
  
)
    
 
Equation 9.2.1 Equation used to fit calibration data. Y is equal to the fluorescence intensity, x is equal to the lipid 
concentration, A1, t1 and y0 are the parameters to be found.  
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The parameters obtained using this fitting were A1 = -432.79, t1 = -3.51 and y0 = 445.25. 
a) b) 
  
Figure 9.2.6 Calculating lipid concentration in each fraction, a) The calibration curve used, the red line shows the data 
fit. b) calculated concentration of lipid in each fraction. Ex/Em = 557/595 nm, buffer D and T = 37°C. The experiment was 
performed three times and the average plotted. The error bars are equal to two standard deviations.  
 
Figure 9.2.6 a was then used as a calibration curve to determine the concentration of lipids in the 
vesicles passed through the Sephadex G-50 column.  
 
DOPC was mixed with 1% Rhodamine PE and dried under a nitrogen stream and lyophilised for a 
minimum of twelve hours. The mixture was then hydrated with buffer D and vesicles extruded as 
described in section 9.2.1. 300µl of this suspension were loaded on to the top filter of the column and 
300µl of vesicle suspension collected. A further 1.5ml of buffer D was added to the column and a 
further 11 lots of 300µl aliquots of vesicle suspension collected. The fluorescence intensity of each 
aliquot was measured (as described above for the calibration) and the concentration of lipid in each 
calculated by rearranging equation 9.2.1 and using the parameters obtained above. The results shown 
in figure 9.2.6 b) are from three independent experiments. From this figure it can be seen that the 
highest concentration of lipid is in fractions 7-10.  
 
9.2.3.4 Vesicle Size 
 
DOPC was hydrated with buffer C and vesicles extruded as described in section 9.2.1. 300µl of this 
solution were loaded on to the top filter of the column and 300µl of vesicle suspension collected. A 
further 1.5ml of buffer D was added to the column and a further 11 lots of 300µl aliquots of vesicle 
suspension collected.  
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The size distribution of the vesicles in fractions 7-9 were measured using dynamic light scattering 
(DLS). Vesicle suspension was placed in an optical glass microcuvette (VWR, UK) and the size 
measured using a Malvern Instruments High Performance Particle Sizer at room temperature 
controlled using Malvern HPPS software. 
These measurements were carried out three times independently to ensure the size distribution was 
consistent.  Figure 9.2.7 shows that the size distribution of each fraction is consistent and that the 
average size of the vesicles increases with fraction number. This size difference between fractions is 
within an acceptable level.  
 
a) b) 
  
c) 
 
Figure 9.2.7 DLS results. These results are of three replicates and were recorded at room temperature.  
 
By combining the results from these control experiments it was decided that fractions 7-9 would be 
used for the Calcein leakage assay. The acceptable level of external Calcein in each fraction would be 
determined by eye in subsequent assays. Vesicle suspension would be collected from fraction 7 
onwards until the suspension turned yellow, indicating that external Calcein was present.  
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9.2.3.5. Effects of C12E8 on Fluorescence 
 
The effects of C12E8 on Calcein fluorescence were also tested. Because C12E8 causes DOPC vesicles to 
burst leading to an increase in Calcein fluorescence, vesicles with 3.0 mM Calcein both inside and 
outside were used.  It was assumed that as the maximum fluorescence intensity is close to this 
concentration any changes in fluorescence would be easily measured.  
DOPC was hydrated with 3.0 mM Calcein in buffer B and vesicles extruded as described in section 
9.2.1. The vesicle solutions were then added to the well plate using micropipette and the fluorescence 
intensity measured. After 30 minutes 1µl of 200mM C12E8 in buffer D, 1µl of buffer D, or no solution 
was added to the wells and the fluorescence intensity measured immediately and then 30 minutes 
later. As a control this was repeated using 3.0 mM Calcein in buffer B with no DOPC present.  
These results are shown in figure 9.2.8.  
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a) d) 
  
b) e) 
  
c) f) 
  
 
Figure 9.2.8 Graphs showing the effect of C12E8 on the fluorescence emission of Calcein. In Graphs a – c Calcein is 
present inside and outside of a DOPC vesicle and in graphs d – f  a solution of Calcein is used with no DOPC present. Ex/ = 
490 nm, buffer D and T = 37°C. The experiment was performed three times and the average plotted. The error bars are equal 
to two standard deviations. 
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The results show that the addition of C12E8 did not cause any significant changes in Calcein 
fluorescence when compared with elution buffer and sample left on its own.   
 
9.2.3.6 Concentration of CAD 
 
The ideal concentration of CAD in DMSO to use in this experiment was determined. Three 
concentrations were tested, 12.5mM, 25mM and 50mM; the amount of the drug in each experiment 
was held constant by using injection volumes of 10µl, 5µl, and 2.5µl respectively.  
Vesicles were made as described in 9.2.1. The desired fractions were collected and buffer D added to 
make the volume of vesicle suspension required for the experiment. 200 µl of vesicle suspension was 
added to the wells by micropipette. The fluorescence intensity was recorded for 30 minutes to ensure 
Calcein was not leaking from the vesicles. After this background scan the three different 
concentrations of SpipC0me in DMSO were added to nine wells (the three experiments were 
triplicated) and the fluorescence monitored for a further 60 minutes. When the 60 minutes had elapsed 
the vesicles in all wells were ruptured by addition of 1µl 200mM C12E8 in buffer D and the 
fluorescence monitored for a further 30 minutes to ensure all dye had been released.  
Figure 9.2.9 shows the normalised fluorescence intensity plotted against time for each of the three 
CAD concentrations.  
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a) b) 
  
c) 
 
Figure 9.2.9 Varying the CAD concentration and volume. Changes in fluorescence intensity can be seen after addition of 
SpipC0me in DMSO at 30 minutes and addition of 200mM C12E8 at 90 minutes to Calcein-containing vesicles. The red 
arrow indicates when C12E8 was added. The amount of drug added was a) 10µl, 12.5mM b) 5µl, 25mM and c) 2.5µl, 50mM.  
The three different colours used represent repeats performed in the same assay. Ex/Em = 490/520 nm, buffer D and T = 
37°C.  
The data were then fitted to the exponential decay function shown in equation 9.2.2, which is inbuilt 
Origin function and the time constant, t1, calculated.  
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Equation 9.2.2 Equation used to fit Calcein leakage assay data. Equation ExpDecay1 in Origin.  
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The average r2 values for each of the concentrations used were a) 0.506903, b) 0.97127 and c) 
0.996953. These results show that using a concentration of 50mM and an injection volume of 2.5µl 
gave rise to data with the best fit for the drug SpipC0me. Higher rates of leakage were observed when 
a larger volume of CAD was used, this is due to faster mixing times. Not all of the drugs in the 
Spiperone analogue series would dissolve in DMSO up to 50mM so a 25mM concentration of drug 
and an injection volume of 2.5µl were used instead. It was also decided that a lower concentration of 
CAD would be used because when the assay is performed using several CADs in one well plate there 
will be a time delay before the fluorescence intensity can be read (the time between the CAD being 
added and the well being read is approximately 3 minutes). As seen in figure 9.2.9 a and 9.2.9 b when 
the rate of reaction is fast the intensity reaches a maximum very quickly. If this occurs too quickly a 
lot of the initial data is lost and the quality of the fit reduced.  
 
9.2.3.7 Volume of Vesicle Solution 
 
It is ideal that the DOPC:CAD ratio is kept as high as possible so to be pharmacologically relevant. 
This can be achieved by using a large number of vesicles. The maximum volume of vesicles that can 
be used in each well is 200µl. This volume of vesicles was tested as well as 100µl to ensure that the 
data for 200µl fitted equation 9.2.2 well. 
Vesicles were made as described in 9.2.3.6 and then added to the well plate by micropipette.  The 
fluorescence intensity was recorded for 30 minutes to ensure Calcein was not leaking from the 
vesicles. After this background scan 2.5µl of 25mM SpipC0me in DMSO were added to three wells 
containing 200µl of vesicles and three wells containing 100µl of vesicles. The fluorescence was 
monitored for a further 60 minutes. When the 60 minutes had elapsed the vesicles in all wells were 
ruptured by addition of 1µl 200mM C12E8 in buffer D and the fluorescence monitored for a further 30 
minutes to ensure all dye had been released.  
Figure 9.2.10 shows the normalised fluorescence intensity plotted against time for these two volumes 
tested. 
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a) b) 
  
 
Figure 9.2.10 Changes in fluorescent intensity at 520nm. Changes can be seen after addition of 2.5µl of 25 mM 
SpipC0me in DMSO to Calcein-containing vesicles. The volume of vesicles used was a) 200µl and  b) 100µl.  The three 
different colours used represent repeats performed in the same assay. Ex/Em = 490/520 nm, buffer D and T = 37°C. 
 
The data were fitted to equation 9.2.2 in section 9.2.3.6 and the average r2 values for each of the 
volumes used were a) 0.996153 and b) 0.98751. These results show that using a volume of 200µl 
vesicles gave rise to data with the best fit for the drug SpipC0me, this also maximises the amount of 
vesicles used per well.   
 
9.2.3.8 The Effects of DMSO on Vesicles 
 
To ensure that DMSO does not cause the vesicles to rupture is was tested in the absence of any CAD.  
Vesicles were made as described in 9.2.3.6.  Three lots of 200µl of vesicles were added to three wells. 
The fluorescence intensity was recorded for 30 minutes to ensure Calcein was not leaking from the 
vesicles. After this background scan 2.5µl of DMSO was added to one well, 1µl of 200mM C12E8 in 
buffer D to another well, and no solution to another well. The fluorescence was monitored for a 
further 60 minutes. When the 60 minutes had elapsed the vesicles in all wells were ruptured by 
addition of 1µl 200mM C12E8 in buffer D and the fluorescence monitored for a further 30 minutes to 
ensure all dye had been released.  
Figure 9.2.11 shows that DMSO does not cause Calcein leakage from vesicles. DMSO increases the 
permeability of membrane bilayer139 and has been shown to cause dye leakage from phospholipid 
vesicles at high enough concentration140. At the concentration used in this assay DMSO does not 
cause Calcein leakage above the background.  
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Figure 9.2.11 Changes in fluorescent intensity at 520nm. The background fluorescence was recorded for 30mins. After 
which the following was added to Calcein-containing vesicles: 2.5µl DMSO (orange plot), 1µl of 200mM C12E8 in buffer D 
(blue plot) nothing (purple plot). The fluorescence intensity was measured for a further 60mins and then 1µl of 200mM 
C12E8 in buffer D added to the vesicles (purple and orange plot). Ex/Em = 490/520 nm, buffer D and T = 37°C.  
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9.2.4 Calcein Leakage Assay 
 
Once the ideal assay conditions had been established all five Spiperone analogues were tested in the 
Calcein leakage assay three separate times and in triplicate each time.  
 
Calcein-containing vesicles were made as described in section 9.2.1. Each time 300µl of vesicle 
solution were loaded on the top filter and excess liquid allowed to drip through. Following this 1ml of 
buffer D was added and collected as waste. A further 1ml of buffer D was added, this was collected 
when the solution ran orange until when yellow droplets came through indicating that they contained 
external Calcein dye; this was repeated three times. The three lots of vesicles collected were 
combined and buffer D was added to make the required volume needed for the assay.  
200µl of vesicle suspension was added to each well and the fluorescence intensity was recorded for 30 
minutes to ensure Calcein was not leaking from the vesicles. After this background scan 2.5µl of 
25mM CAD in DMSO were added to each well and the fluorescence monitored for a further 60 
minutes. As a control, 2.5µl of DMSO was added to one well and no solution added to another well.  
When the 60 minutes had elapsed the vesicles in all wells were ruptured by addition of 1µl of 200mM 
C12E8 in buffer D and the fluorescence monitored for a further 30 minutes to ensure all dye had been 
released.  
The time constant, t1, of Calcein leakage was determined by plotting the fluorescence intensity – time 
data to equation 9.2.2.  
The measured fluorescence intensity after addition of CAD, f(t), was normalised to obtain the efflux 
function E(t) in equation 9.2.3, taken from a paper by Rex141. In this equation fe is equal to the 
maximum fluorescence intensity when the vesicles are ruptured with C12E8, ft is equal to the 
fluorescence intensity at a specific time point, t, after adding the CAD and fb is equal to the 
background fluorescence intensity before CAD is added to the vesicles. 
 
 
  ( )   
       
      
 
Equation 9.2.3 Equation used to calculate E (t).   
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The percentage of Calcein leakage was then calculated using equation 9.2.4141.  
                  (   ( ))      
Equation 9.2.4 Equation used to calculate percentage Calcein leakage.  
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9.3 Results 
9.3.1 Rate of Calcein Leakage  
 
The rate constant of Calcein leakage, t1 (defined in section 9.2.4 and equation 9.2.1), was calculated. 
To determine the effect increasing the central carbon chain length has on the disruption of DOPC 
vesicles the molecular weight of the Spiperone analogues were plotted against 1/t1 (figure 9.3.1) 
Lower values of t1 and higher values of 1/t1 correspond to a faster rate of Calcein leakage. 
a) b) 
  
c) 
 
 
Figure 9.3.1 Graphs of the rate of Calcein leakage versus molecular weight of the CAD. Ex/Em = 490/520 nm, buffer D 
and T = 37°C. The graphs show results recorded on three separate occasions. On each occasion the experiment was 
performed in triplicate and the average plotted. The error bars are equal to two standard deviations. 
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9.3.2 Percentage of Calcein Leakage  
 
The percentage of Calcein leakage (defined in section 9.2.4 and equation 9.2.4) was calculated. To 
determine the effect increasing the central carbon chain length has on the disruption of DOPC vesicles 
the molecular weight of the Spiperone analogues were plotted against this percentage (figure 9.3.2).  
 
 
a) b) 
  
c)  
 
 
Figure 9.3.2 Graphs of the percentage Calcein leakage versus molecular weight of the CAD. Ex/Em = 490/520 nm, 
buffer D and T = 37°C. The graphs show results recorded on three separate occasions. On each occasion the experiment was 
performed in triplicate and the average plotted. The error bars are equal to two standard deviations. 
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9.4 Discussion  
 
The CAD interaction and disruption of a phospholipid bilayer causing Calcein leakage has been 
observed previously with oligomers142 and peptides143.  In these studies the leakage was quantified as 
a percentage of Calcein efflux.   
Figure 9.3.1 shows that as the central carbon atom chain in the Spiperone analogues is increased so 
does the rate of Calcein efflux. The outlier to this trend is SpipC0me in result figure 9.3.1 a but the 
data are very noisy in this case.  
The rate of Carboxyfluorescein (another self quenching fluorescent dye) leakage from vesicles 
disrupted by a peptide was previously investigated144. In this work they speculate that the peptide 
binds to the outer leaflet of the lipid vesicles and then transiently inserts into the bilayer hydrophobic 
core. When the peptide is in the hydrophobic core an apparent pore is formed and Carboxyfluorescein 
leaks from the vesicle. Then the peptide crosses the bilayer and the rate of Carboxyfluorescein efflux 
becomes very slow or eventually stops144. This mechanism could be responsible for the results 
observed with CADs, as the initial rate of leakage is high but eventually plateaus and in the large 
majority of the experiments does not reach the maximum Calcein leakage seen when detergent is 
added. This mechanism for peptide – vesicle interaction is illustrated in figure 9.4.1. The rate of dye 
leakage from vesicles in the model used in this paper were dependent on the rate of bilayer 
dissociation (koff), the rate of insertion into the hydrophobic core (kins) and the rate of extraction (kdins).   
  
134 
 
 
 
Figure 9.4.1 Scheme of the model for peptide-induced transient pore formation and peptide translocation across the 
lipid bilayer. The α-helices are shown as cylinders (in cross section on the right), where the darker half-circles represent the 
hydrophobic faces and the lighter half-circles represent the hydrophilic faces. Also indicated are the apparent rate constants 
for each process144. Image taken from paper by Yandek et al144.  
 
These results correlate with the CHI_IAM results in section 8.3.3.2 where increasing the carbon chain 
length in the CADs led to an increase in the solubility of the CADs in the immobilised lipids. This 
correlation could be explained as follows. The CAD passes through the bilayer from one side to the 
other forming a temporary pore in the bilayer from which Calcein leaks. A higher proportion of the 
larger CADs will aggregate in the DOPC bilayer so a larger number of pores or larger pores will be 
created leading to an increase in Calcein leakage.  
The larger CADs could also have a greater effect on the permeability of the bilayer, so causing a 
higher rate of Calcein leakage than the smaller CADs. A previous study has shown that drugs can 
cause an increase in the permeability of vesicles and cells145.  
The pH dependent Calcein release from phospholipid vesicles containing N-acyl amino acids has been 
observed138. The authors speculate that this pH effect involves a permeability change induced by 
protonation at low pH of  the N-acyl amino acids whilst remaining in the membrane. They also 
speculate that this release is controlled by amino acid and phosphatidylcholine head group 
interactions. Because of the greater solubility of the larger CADs in the bilayer, a larger proportion 
will be present in the bilayer. They may be present in their protonated state in the membrane and 
interacting with the lipid head group leading to an increase in bilayer permeability. 
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In the results shown in figure 9.3.2, it can be seen that there is no correlation between the molecular 
weight of the CAD and the extent of Calcein efflux. One would expect the percentage leakage to be 
approximately the same for each drug. In each case SpipC2me has the lowest percentage of Calcein 
leakage. For the other drugs the change in fluorescence intensity has reached a plateau, but because of 
the slow rate of Calcein leakage for SpipC2me the data have not reached this plateau after 60 minutes 
and a lower percentage of Calcein leakage is recorded.    
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9.5 Chapter Summary 
 
A fluorescence based assay for measuring the effects of CADs interacting with lipid vesicles was 
optimised. A number of controls were undertaken to ensure adequate vesicle dye separation and that 
any fluorescence intensity changes were due to the CAD interacting with the membrane. This was 
done by testing the effects of C12E8 on Calcein fluorescence and was shown to have no significant 
effect on fluorescence measured at 520nm. The control experiments lead to an assay for which 100nm 
Calcein-containing lipid vesicles were disrupted with 2.5µl of 25mM CAD in DMSO solution. Upon 
CAD addition, Calcein was released from the vesicles into the solution and an increase in 
fluorescence intensity measured. This assay was performed for all Spiperone analogues three times.  
Data were collected and fitted with an exponential decay from which the percentage of Calcein 
leakage and the rate constant of Calcein efflux could be calculated. It was found that the rate of 
Calcein leakage increased with increasing CAD size. This result suggests that the larger CADs have a 
greater interaction with the DOPC bilayer; this correlates with the CHI_IAM measurements where the 
larger CADs were found to have a greater interaction with the immobilised membrane.  
These results combined have provided a means to gain further insight into the interaction of drug 
molecules with lipid membranes at a molecular level. 
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10 Rapid Cyclic Voltammetry  
10.1 Introduction 
 
RCV is a type of potentiodynamic electrochemical measurement.  In an RCV experiment, the working 
electrode potential is swept linearly and rapidly between two limits at the desired scan rate, ν (~40 
mVs-1), whilst the current, i, is recorded as a function of the applied potential, E, to produce a cyclic 
voltammogram, which is also referred to as a scan. Cyclic voltammetry is the most widely used 
technique for acquiring qualitative information about electrochemical reactions. The power of cyclic 
voltammetry results from its ability to rapidly provide considerable information on the 
thermodynamics of redox processes and the kinetics of heterogeneous electron-transfer reactions.  It 
also provides  information on adsorption processes occurring at the electrode interface146.  
Platinum working electrodes fabricated using lithography techniques on which a thin film of Hg is 
deposited have been used extensively for studying the adsorption and desorption of surface organic 
films147. This electrode system has been used to support self-assembled phospholipid monolayers 
which are dynamic surface coatings with unique dielectric properties. This system is ideal for this 
application due to its atomically smooth surface and hydrophibicity at its potential of zero charge 
(PZC)148.  
Studies have shown that around the PZC of Hg, phospholipid layers are configured with their alkyl 
chains next to the Hg and their polar heads in solution149, 150. This configuration mimics one half of a 
phospholipid bilayer. At higher negative potentials, the Hg surface changes from being apolar to polar 
and the phospholipid layers break up by a series of two phase transitions into a system of bilayer 
islands and uncoated Hg. At more negative potentials, the phospholipid layer desorbs and is replaced 
by electrolyte147.  
RCV is a very powerful tool for monitoring structural changes of phospholipid monolayers on Hg 
electrodes because these phase transitions result in two capacitance peaks being observed in the 
voltammogram of the DOPC monolayer. These peaks represent phase transitions due to reorientation 
of the layer in response to the increasing applied negative potential151-156. 
This system of a DOPC monolayer on a Hg/Pt electrode has been used to investigate ion transport 
through both peptide and protein ion channels157 and electron and proton transfer to redox active co-
enzymes in particular ubiquinone-10158.  
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This system has also been used to study the magnitude of the interaction of Silica nanoparticles148, 
ionic liquids159, drugs153, cations160, polyaromatic hydrocarbons161 and organic micro pollutants162 with 
a DOPC monolayer. In these studies the monolayer phase transition peaks were depressed and 
broadened. By measuring the change in height of these peaks, changes to the order and fluidity of the 
monolayer can be examined.  
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10.2 Materials and Methods 
10.2.1 Sample Preparation 
 
Fresh CAD solutions were made by dissolving CADs in Methanol at a concentration of 0.25mM and 
were then used immediately.  
Buffer E (10mM PBS, 0.138mM NaCl, 0.0027mM KCl, pH 7.4), was purchased as a pre-made sachet 
from Aldrich Chemical Co. (Gillingham, UK) and made up using Milli-Q water.   
DOPC solutions were made by dissolving powdered DOPC into buffer E, which was stored in the 
fridge until use. Prior to injection into the electrochemical cell, these solutions were bubbled with 
argon gas to remove O2. 
 
10.2.2 Rapid Cyclic Voltammetry  
 
The microfabricated Pt/Hg film electrodes were supplied by the Tyndall National Institute and are 
exhaustively described elsewhere152, 153. Pt discs with a radius of 0.480 mm were embedded on a 
silicon wafer substrate, connected via Si3N4-insulated interconnections to 2.54 mm Pt electrical 
contacts. Deposition of Hg on to these Pt discs was carried out using a pipette in order to produce a 
Hg film with surface area of 0.744 mm2, calculated for the semioblate spheroid geometry163. The Hg 
film electrode (MFE) was then rinsed with Milli-Q water and dried under nitrogen gas before use. 
Before each experiment, all glassware and internal components of the electrochemical cell were 
cleaned with 50 °C piranha solution (30 wt % H2O2 + 98 wt % H2SO4 in ratio 2:1) for 10 minutes and 
then rinsed with Milli-Q water.  
 
The flow system consisted of (i) a peristaltic pump (Cole-Parmer Instrument Co., cat. no. 7554-20), 
(ii) two universal valve-switching modules (Anachem Ltd.), (iii) a 10 l electrolyte reservoir, (iv) two 
25ml sample cells (v) magnetic stirrers for the solutions in the electrolyte reservoir and the sample 
cell, and (vi) a 0.75ml flow cell.   
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Figure 10.2.1 The flow cell used in RCV experiments.  
 
 
The flow cell shown in figure 10.2.1 contained a sampling port for the injection of phospholipid or 
CAD solutions. All parts were connected to each other by Teflon and silicon tubing. The flow cell 
was made from plexiglass with a silicon rubber seal. A Ag/AgCl 3.0 mol l-1 KCl REF201 Red Rod 
reference electrode (VWR International Ltd.) was fitted into the cell, and all potentials in this work  
are quoted versus the potential of this electrode.  
 
For RCV measurements, the wafer-based electrode was installed inside a flow cell. From the 
reservoir, a constant flow of buffer E was passed over the electrode surface. A flow rate of 5–10 
ml min–1 was used. The electrodes were connected to the Autolab PGSTAT 30 potentiostat 
(Ecochemie, Utrecht, Netherlands) and all RCV measurements were carried out with a PowerLab 4/25 
signal generator (AD Instruments Ltd.) which was controlled by Scope software (AD Instruments 
Ltd.).  
In RCV the current at the working electrode is plotted versus the applied voltage to give the cyclic 
voltammogram trace that can visualize the conformational change of the phospholipids at the 
Hg/electrolyte interface. 
Before each measurement the Hg electrode was cleaned by cycling the potential between −0.4 V and 
−2.8 V at a scan rate of 40Vs-1 and a fresh DOPC coating was deposited on the Hg from a1mg/ml 
dispersion in buffer E of which 0.1-0.2 ml was injected into the flow cell. This scan rate was chosen 
because the resulting current peaks were significant enough to be recorded at a good resolution whilst 
maintaining a good signal-to-noise ratio. The specific capacitance (Csp) was calculated from the RCV 
current (I) using equation 10.2.1, where A0 is the electrode area and   is the scan rate.  
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Equation 10.2.1 Calculating the specific capacitance (Csp) from the current (I), scan rate (ν) and electrode area (A0).  
 
The potential was then cycled between -0.4V and -1.8V to determine the integrity of the deposited 
DOPC layer by monitoring the capacitance peaks characteristic of successive electrically induced 
phase transitions in the DOPC monolayers147, 156, 164. A typical voltammogram of this process is shown 
in figure 10.2.2.  
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Figure 10.2.2 A rapid cyclic voltammogram of a DOPC-coated Pt/Hg electrode. Buffer E, room temperature (RT), ν = 
40Vs-1.  
 
The potential was then cycled between -0.4V and -1.2V to determine the background reading of a 
DOPC-coated Pt/Hg electrode in the absence of CADs; a typical voltammogram of this process is 
shown in figure 10.2.3.  
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Figure 10.2.3 A rapid cyclic voltammogram of a DOPC-coated Pt/Hg electrode in the absence of CADs. Buffer E, RT, 
ν = 40Vs-1. 
Subsequently, sample solutions of CAD in methanol were injected into the flow cell and the 
interaction of the CAD with the DOPC monolayer was monitored whilst cycling the electrode 
potential between -0.4V and -1.2V at 40Vs-1.  Voltammograms were recorded at 1s intervals for 60s. 
The flow of the CAD solution was stopped and a final scan recorded once the capacitance peak 
heights and positions had stabilised.  
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10.3 Results 
 
These experiments were performed to examine the interaction of CADs with a DOPC monolayer on a 
Pt/Hg electrode. The Spiperone analogues (described in section 6.1.2) were tested in this system to 
ascertain the effect small changes to the drugs structure had on this interaction. The eight CNS drugs 
(described in section 6.1.1) were also tested in this system to determine whether the strength of this 
interaction correlated with their in vivo non-specific binding values and in silico interaction energies82 
(discussed in section 5.2.4.3).  
 
10.3.1 DOPC Monolayer 
 
A voltammogram of a DOPC monolayer on a Pt/Hg electrode was recorded as described in section 
10.2.2. The purple trace in figure 10.3.1a shows a voltammogram of a DOPC monolayer in the 
absence of CAD. In the voltammogram two sharp pseudo-capacitance peaks are observed; these peaks 
represent phase transitions in the DOPC monolayer. Figure 10.3.1 b shows a schematic of the phase 
transitions corresponding to the region of the voltammogram labelled in figure 10.3.1 a. These phase 
transitions have been characterised utilizing metal ion reduction165, 166.  
As the potential is scanned from -0.4 V to -0.8 V there is no change in the capacitance of the 
monolayer and the monolayer capacitance is low (~ 2.0 µF cm-2). Studies have shown that the 
monolayer is impermeable to metal ions in the surrounding solution and has a highly regular, defect-
free structure; this state is labelled A in figure 10.3.1 b 165, 166.  
Scanning the potential further negative (from -0.8 V to -1.0 V) introduces a stress into the system 
caused by the potential drop across the monolayer, similar to the effects of osmotic stress. In both 
cases, pores are created in the lipid layer, due to osmotic or interfacial tensions165. Studies have shown 
that the creation of various pores and defect regions in the monolayer allows metal ions access to the 
electrode surface. The rate of electrolyte ion penetration through the layer (measured as current and 
converted to pseudo-capacitance) is correlated to the size and density of pores in the lipid layer165.  
This phase transition of a monolayer with a regular structure to one with pores and defects present is 
observed as a capacitance peak at ~ -0.925 V and is labelled B in figure 10.3.1 b. The second phase 
transition peak at ~ -0.975 V represents a process involving the growth and coalescence of defects in 
the phase formed in the first transition166 leaving bilayer lipid islands and uncoated Hg and is labelled 
C in figure 10.3.1 b.  
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The capacitance peaks at these negative potentials arise out of a competition between the polar heads 
and hydrophobic tails of the phospholipid for access to the interface150. Complete bilayer formation, 
involving displacement of lipid tails by water, does not occur in the first phase transition as this would 
require 50% of the Hg surface to be covered by water and this is energetically unfavourable150. In the 
second phase transition lipid tails are desorbed from the surface and bilayer structures are formed. 
This is because at the higher potential there is a greater energy gain from the full adsorption of the 
lipid head groups and this enables the displacement of tails by water to be more energetically 
favourable150. 
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10.3.2 DOPC-MeOH Control 
 
As a control experiment pure methanol was injected into the flow cell to determine if methanol had 
any effect on the DOPC monolayer. Figure 10.3.2 shows voltammograms before (orange trace) and 
after (purple trace) MeOH was passed through the flow cell for 60 seconds at a flow rate of 5-10 
ml/min. The only change in the voltammogram after MeOH injection is the heights of the capacitance 
peaks of the reverse scan (-1.2V to -0.4V) have been slightly reduced and are on average 87% the 
height of the DOPC peak before interaction with MeOH. This implies that MeOH does not affect the 
formation of pores and defects in the monolayer but has a small effect on the reformation of the 
DOPC monolayer. 
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Figure 10.3.2 Rapid cyclic voltammograms of a DOPC coated Pt/Hg electrode. Before (orange) and after (purple) 
MeOH flow. Buffer E, RT, ν = 40Vs-1.  
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10.3.3 DOPC Monolayer-CAD Interactions 
 
Voltammograms of a DOPC monolayer on a Pt/Hg electrode interacting with CADs were then 
recorded as described in section 10.2. A DOPC monolayer was formed before injection of CAD 
solution into the flow cell and the peak height, peak position, and monolayer capacitance at -0.7 V 
recorded as a control. Figures 10.3.3 and 10.3.4 show the voltammograms for the Spiperone 
analogues tested and eight of the ten well characterised CNS drugs tested respectively. The 
voltammograms of the DOPC monolayer before interaction with the CADs (orange) show 
characteristic capacitance peaks. A solution of CAD was passed through the flow cell for 60 seconds 
at a flow rate of 5-10 ml/min and the voltammogram recorded. After 60 seconds the CAD solution 
was replaced with buffer E and the CAD solution washed from the cell. Voltammograms were then 
recorded once the capacitance peak heights and positions had stabilised. The blue trace in figures 
10.3.3 and 10.3.4 show the voltammogram recorded after 60 seconds of interaction with CAD 
solution and the purple trace is the voltammogram of the recovered monolayer.  
For all the CADs tested depressions of both capacitance peaks in both scan directions were observed. 
In all cases these capacitance peaks were shifted to more positive potentials relative to the DOPC 
control. For some of the CADs tested a significant increase in the monolayer capacitance at -0.7 V 
was also observed.  
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Figure 10.3.3 Rapid cyclic voltammograms of DOPC coated Pt/Hg electrodes prior to injection of CAD into the flow cell 
(orange), 60 seconds after injection (blue), and the stabilised peak after flow of CAD was stopped (purple). a) SpipC0me, b) 
SpipC2me, c) SpipC3me, d) SpipC4me, and e) SpipC6me. [CAD] = 0.25mM, ν = 40Vs-1, buffer E, pH = 7.4.  
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Figure 10.3.4 Rapid cyclic voltammograms for DOPC coated Pt/Hg electrodes prior to injection of CAD into the flow cell 
(orange), 60 seconds after injection (blue), and the stabilised peak after flow of CAD was stopped (purple). a) DASB, b) 
Diprenorphine, c) Fallypride, d) Flumazenil, e) Raclopride, f) Rolipram, g) Spiperone, and, h) WAY. [CAD] = 0.25mM, ν = 
40Vs-1, buffer E, pH = 7.4.  
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10.4 Discussion 
10.4.1 Capacitance Peak Depression 
 
The pseudo-capacitance peaks are reduced and broadened for all of the CADs tested; this has been 
observed previously with polycyclic aromatic hydrocarbons161, drugs153,  and ionic liquids159 
interacting with a DOPC monolayer. Previous work has also shown that the adsorption of silica 
nanoparticles onto a DOPC monolayer causes depression of the capacitance peaks.  Other 
measurements in this work showed that the silica particles lowered the mobility of  the monolayer148.  
The potential at which the phase transitions detailed in section 10.3.1 occur will depend upon the 
energetics of the growth of the new phases from the potential-induced defects. When the DOPC 
monolayer is well-ordered, the lipids are energetically homogeneous and the phase transitions will 
occur at a single value of the potential resulting in sharp pseudo-capacitance peaks. When the 
monolayer is disordered by interaction with a substrate, the potential-induced defects will be 
energetically heterogeneous and the phase transition will occur over a larger potential range, causing 
the pseudo-capacitance peaks to become depressed and broadened148. The height of these pseudo-
capacitance peaks is therefore a sensitive indication of the degree by which the substrate disorders the 
monolayer.  The drug can cause disorder to the monolayer by penetrating the monolayer or by 
interacting with the lipid head group. These two effects are measured by a change in monolayer 
capacitance (section 10.4.2) and a change in the potential of the capacitance peaks (section 10.4.3) 
respectively. The depression of the capacitance peak is caused by both of these types of drug-lipid 
interaction.  
The extent by which the CADs disrupt the DOPC monolayer was interrogated by measuring the 
reduction in the height of the pseudo-capacitance peaks in the forward and reverse scans. This 
measurement allows indirect probing of the interaction of the CAD with the DOPC monolayer. It is 
expected that  CAD interaction with the DOPC head groups would not change the monolayer 
capacitance significantly, but would result in modification of the capacitance peaks165.  
As the potential is scanned negatively the layer becomes porated and strongly defective (as described 
in section 10.3.1) and the CAD molecules can interact with these holes/defects. The potential is then 
scanned positively, back to the initial potential value and the structural characteristics of 
the reformed layer observed.   The reformation of the defect-free monolayer will be altered by 
incorporation or interaction with the CAD, which will again be apparent by changes to the height of 
the capacitive peaks.   
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The average of the height of the pseusdo-capacitance peaks as a percentage of the original peak height 
before CAD interaction was calculated. Figure 10.4.1 shows the peak height depression percentage 
plotted against the molecular weight of the five Spiperone analogues tested for both the forward (a) 
and reverse (b) scan direction. These plots show that as the size of the Spiperone analogue is 
increased so does the amount by which it disrupts the DOPC monolayer, which is measured as a 
reduction in the pseudo-capacitance peak heights. Both of these sets of data were fitted to a linear plot 
and the r2 value for this fitting was 0.78 for the forward scan and 0.92 for the reverse scan. This 
increase in the strength of the interaction as a carbon chain length is increased has been seen in 
previous work using ionic liquids159.  These results correlate with what was observed in section 
8.3.3.2 and 9.3 that the larger Spiperone analogues have the largest interaction with DOPC.   
The phase transition peak height depression was approximately equal for the forward scan and the 
reverse scan, expect for SpipC6me where the peak was depressed more in the reverse scan than in the 
forward scan.  
 
a)   b)  
  
Figure 10.4.1 Graph showing peak suppression against molecular weight for the Spiperone analogue series. a) forward 
scan b) reverse scan. [CAD] = 0.25mM, ν = 40Vs-1, buffer E, pH = 7.4. The peak height depression is the height of the 
depressed peak as a percentage of the original peak before CAD interaction. The values are for an average of three 
experiments and the error bars represent two standard deviations. The orange line shows the linear fit of the data.  
 
The peak height depression percentage was also calculated for the CNS drugs tested and plotted 
against the in vivo non-specific binding vales82 (figure 10.4.2) and against the in silico interaction 
energies with a DOPC molecule82 (figure 10.4.3) for both the forward scan (a) and the reverse scan 
(b).  
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There is a linear correlation between the CAD-DOPC monolayer interaction and the in vivo non-
specific binding with an r2 value of 0.87 for the forward scan and a linear correlation with a much 
smaller r2 value of 0.62 for the reverse scan.   
This result implies that the in vivo non-specific binding of a CAD is influenced by the extent to which 
it interacts with a lipid membrane, so the larger the interaction with the lipid membrane the more the 
CAD aggregates in the cell membrane leading to a high value of non-specific binding observed in 
PET imaging. This depression of the first capacitance peak in the forward scan has a larger correlation 
with in vivo non-specific binding than lipophilicity measurements or in silico measurements. This 
technique could therefore be used to screen candidate drugs and radioligands to predict their non-
specific binding values (discussed in section 5.2.4). An assay that can select compounds that display 
the greatest likelihood of success would be extremely valuable due to the high cost and low-
throughput nature of PET imaging. 
There is also a strong linear correlation between the CAD-DOPC monolayer interaction for the 
forward scan and the in silico DOPC interaction energy described in section 5.2.4.3 with an r2 value 
of 0.94. The plot of peak depression in the reverse scan versus interaction energy also has a linear 
correlation but with a much smaller r2 value of 0.66.  
The degree by which the CADs disturbed the monolayer was greater on the forward scan (-0.4 V to -
1.2 V) than for the reverse scan (-1.2 V to -0.4 V), or approximately the same. These differences in 
the peak height depression percentages for the forward scan and reverse scan imply that the CADs 
interact with the monolayer at lower negative potentials and so affect the phase transition in the 
forward scan. Then at higher negative potentials some of the CAD is displaced from the DOPC layer 
and so has less of an effect on the phase transition when the potential is swept in the positive 
direction.  
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a) b) 
  
Figure 10.4.2 Graphs showing the percentage peak suppression against non-specific binding, V2-1 for eight of the well 
characterised CNS drugs. a) forward scan b) reverse scan. [CAD] = 0.25mM, ν = 40Vs-1, buffer E, pH = 7.4. The values 
are for an average of three experiments and the error bars represent two standard deviations (except for Fallypride where 
n=2). The orange line shows the linear fit of the data. 
 
 
a)  b)  
  
Figure 10.4.3 Graphs showing the percentage peak suppression against interaction energy for eight of the well 
characterised CNS drugs. a) forward scan b) reverse scan. [CAD] = 0.25mM, ν = 40Vs-1, buffer E, pH = 7.4. The values 
are for an average of three experiments and the error bars represent two standard deviations (except for Fallypride where 
n=2). The orange line shows the linear fit of the data. 
  
0 20 40 60 80 100 120 140 160 180
0
10
20
30
40
50
60
70
80
 
 
P
ea
k 
H
ei
gh
t D
ep
re
ss
io
n 
/ %
V2-1 / mL g
-1
0 20 40 60 80 100 120 140 160 180
10
20
30
40
50
60
70
80
 
 
P
ea
k 
H
ei
gh
t D
ep
re
ss
io
n 
/ %
V2-1 / mL g
-1
0 -5 -10 -15 -20 -25 -30
0
10
20
30
40
50
60
70
80
 
 
P
ea
k 
H
ei
gh
t D
ep
re
ss
io
n 
/ %
Interaction Energy / Kcal mol-1
0 -5 -10 -15 -20 -25 -30
10
20
30
40
50
60
70
80
 
 
P
ea
k 
H
ei
gh
t D
ep
re
ss
io
n 
/ %
Interaction Energy / Kcal mol-1
154 
 
10.4.2 Monolayer Capacitance Increase 
 
Another change to the voltammograms after CAD addition was the increase in the monolayer’s 
pseudo-capacitance in the potential region from -0.4 V to -0.7 V. Direct insertion of a CAD into the 
DOPC monolayer causes it to become more permeable to the surrounding electrolyte and this leads to 
an increase in the monolayer capacitance165. The insertion of the CAD into the lipid matrix causes a 
significant decrease in the lipid order and a large number of defects are formed preventing the 
reformation of a defect-free DOPC monolayer, so an increase in monolayer capacitance is also 
observed in the reverse scan165.  
The monolayer capacitance at -0.7 V was measured before and after injection of CAD solution into 
the flow cell. Figure 10.4.4 shows the change in capacitance plotted against the molecular weight of 
the Spiperone analogues tested.  For both the forward (shown in purple) and the reverse (shown in 
orange) scans the monolayer capacitance change increases with increasing size of the Spiperone 
analogue. This suggests that the larger CADs penetrate the DOPC monolayer to a larger degree and so 
cause a larger increase in the permeability of the monolayer. This results correlates with the Calcein 
leakage assay results (section 9.3) where the larger CADs were shown to have a greater effect on the 
DOPC bilayers permeability.  
 
Figure 10.4.4 Graphs showing the change in minimum capacitance at -0.7 V for the Spiperone Analogues. Forward 
scan (purple) and reverse scan (orange). [CAD] = 0.25mM, ν = 40Vs-1, buffer E, pH = 7.4. The values are for an average of 
three experiments and the error bars represent two standard deviations. 
 
This change in monolayer capacitance was also calculated for the eight CNS drugs. The changes in 
capacitance were plotted against the in vivo non-specific binding value (figure 10.4.5 a and b) and the 
in silico DOPC interaction energy (figure 10.4.5 c and d) that have been measured previously for 
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these drugs82.  There is a very strong correlation between the changes in capacitance of the monolayer 
in the forward scan and both the in vivo non-specific binding and the in silico DOPC interaction 
energy. Both of these correlations have an r2 value of 0.96. There is little correlation between these 
values and the change in monolayer capacitance for the reverse scan.  
This result implies that the in vivo non-specific binding of a CAD is influenced by the extent to which 
it penetrates the lipid membrane. The larger the penetration of the membrane the more the CAD non-
specifically binds to cell membranes. Again, there is a larger correlation between the in vivo non-
specific binding and these results than there is between the lipophilicity or in silico measurements82.   
This measurement could therefore be used to predict a drug’s non-specific binding value as it is a 
much better predictor than any methods explored previously.  
a)  b)  
  
c)  d) 
  
Figure 10.4.5 Graphs showing the change in monolayer capacitance at -0.7 V for eight of the well characterised CNS 
drugs plotted against in vivo non-specific binding and against in silico interaction energy. a) and c) show this for the 
forward scan. b) and d) show this for the reverse scan. [CAD] = 0.25mM, ν = 40Vs-1, buffer E, pH = 7.4. The values are for 
an average of three experiments and the error bars represent two standard deviations (except for Fallypride where n=2).  
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10.4.3 Peak Potential Shift 
 
The potential at which the phase transition peaks occurred after CAD injection into the flow cell was 
shifted positively relative to the phase transition potential of pure DOPC monolayer.  The phase 
transitions are taking place at a lower potential, meaning incorporation of CADs into the monolayer 
makes these transitions energetically more favourable.   
The shift in potential of the pseudo-capacitance peak has been seen previously for polynuclear 
aromatic hydrocarbons (PAHs)162, when these compounds interact with the DOPC monolayer they 
shift the capacitance peak to a more negative potential. The peak shift is greater for PAHs that contain 
a larger number aromatic rings.  
The behaviour of phospholipids with varying head group surface affinity at the mercury-water 
interface has been studied previously150. In this work it was found that decreasing the surface affinity 
of the head group caused the phase transition peak to be shifted to a higher negative potential. The 
potential at which the first phase transition occurs is related to the surface affinity difference between 
the lipid heads and lipid tails.  
Changing the pH of the electrolyte solution has also been seen to cause a shift in the potential of the 
capacitance peaks160. The potential of the first capacitance peak was shifted positively when the pH 
was decreased from 8.1 to 1.0. In the same paper the type of cation present in the electrolyte has also 
been shown to have an effect of the potential at which the first phase transition occurs160. The amount 
by which the cation shifts the potential of the first capacitance peak in the positive direction follows 
the order: Ca2+ = Mg2+ > Li+ > Na+ > K+ > Cs+. It is noted that this shift correlates with the binding 
order of the cations to phosphatidic acid168.  Due to these findings the authors proposed the following 
hypothesis of the molecular mechanism underlying the phase transitions. A critical electric field is 
required for reorientation of the lipid monolayer. At negative potentials, binding of the electrolyte 
cation with the phosphate group in the polar head is induced, since the negative potential increases the 
association constant of the polar head group with the cation. This cation binding to the phospholipid 
head group alters the electric field across the monolayer and influences the potential at which the 
monolayer reorganises160.  
A positive shift in the phase transition potentials caused by the CADs could be due to them increasing 
the affinity of the head groups for the electrode surface. The CADs bind to the phospholipid head 
group, these drugs are basic so a large proportion will be protonated at pH 7.4, so the head group 
region then has a net positive charge and this increases the head group affinity for the electrode 
surface meaning the first phase transition is energetically more favourable and occurs at a lower 
potential.  
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Figure 10.4.6 shows the potential shift for capacitance peak 1 after injection of the Spiperone 
analogues into the flow cell. The amount by which the peaks are shifted is of the same magnitude as 
with the cations discussed above (~ 10 – 50 mV160). The three analogues in the middle of the size 
range shifted the capacitance peaks more than the two analogues at the extremes but the error in these 
measurements is very large. These results suggest that the three intermediate sized analogues bind 
more to the lipid head group than either SpipC0me or SpipC6me.  
 
 
 
Figure 10.4.6 Graphs showing the potential change of capacitance peak 1 versus molecular weight for the Spiperone 
analogues. [CAD] = 0.25mM, ν = 40Vs-1, buffer E, pH = 7.4. The values are for an average of three experiments and the 
error bars represent two standard deviations. The values are for the forward scan.  
 
Table 10.4.1 shows the potential shift for capacitance peak 1 after injection of the CNS drugs into the 
flow cell. The amount by which the peaks are shifted is much larger than for the Spiperone analogues, 
except for the drugs Rolipram and WAY, which cause a very small peak shift. These results do not 
correlate with the in vivo non-specific binding or in silico interaction energy like the previous 
measurements in sections 10.4.1 and 10.4.2, however, Spiperone causes a much larger peak shift than 
the other drugs and it also has a much larger in vivo non-specific binding.  
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Table 10.4.1 The potential change of capacitance peak 1 for the CNS drugs. [CAD] = 0.25mM, ν = 40Vs-1, buffer E, pH 
= 7.4. The values are for an average of three experiments (except Fallypride where n=2).   
CAD Average Peak Shift / mV Standard Deviation / mV 
Spiperone 158.3 3.8 
WAY 15.8 38.4 
Rolipram -5.0 6.6 
DASB 97.5 11.5 
Flumazenil 95.8 7.6 
Fallypride 85.0 10.6 
Raclopride 71.3 5.3 
Diprenorphine 117.5 14.1 
 
As discussed previously, the reduction in the height of the capacitance peak is due to the drug 
interacting with the DOPC monolayer and disrupting its regular structure. A contribution to this 
disorder is the disruption caused by the drug inserting directly into the monolayer, the magnitude of 
which is measured as the increase in the monolayer capacitance. Another contribution is the disorder 
caused by the drug binding to the head group of the lipid, which is measured as the potential shift in 
the capacitance peak. The combination of these results (shown in table 10.4.2) has lead to the 
following conclusion as to the binding mode of these CNS drugs to the DOPC monolayer. 
 
Table 10.4.2 The average change in monolayer capacitance, average peak shift of capacitance peak 1 and height of 
capacitance peak 1 as a percentage of original peak height after injection of CNS drug into sample cell. [CAD] = 
0.25mM, ν = 40Vs-1, buffer E, pH = 7.4. The values are for an average of three experiments (except Fallypride where n=2). 
All these values relate to the forward scan (-0.4 V to -1.2 V).   
CAD Average 
Monolayer 
Capacitance 
/ µF cm-2 
Standard 
Deviation  
/ µF cm-2 
Average 
Peak Shift 
/ mV 
Standard 
Deviation  
/ mV 
Capacitance 
Peak Height 
/ % 
Standard 
Deviation 
/ % 
Spiperone 7.4 0.3 158.3 3.8 18.8 0.2 
WAY 1.8 0.4 15.8 38.4 38.6 4.7 
Rolipram 0.9 0.2 -5.0 6.6 50.4 5.1 
DASB 3.8 1.4 97.5 11.5 38.3 5.0 
Flumazenil 0.7 0.8 95.8 7.6 43.1 3.5 
Fallypride 2.7 0.9 85.0 10.6 48.1 3.9 
Raclopride 0.8 0.2 71.3 5.3 52.3 1.9 
Diprenorphine 2.2 1.3 117.5 14.1 33.3 1.7 
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Spiperone inserts into the monolayer to a larger degree than any of the other CNS drugs, causing the 
largest increase in monolayer capacitance and binds to the head group region more causing the largest 
potential shift of the first phase transfer peak. Both of these sources of disorder lead to it having the 
largest disruptive interaction and thus the greatest degree of peak height depression.  
Diprenorphine causes the second largest shift in the potential of the first phase transition peak, but 
unlike Spiperone only has an intermediate value for the increase in monolayer capacitance. These two 
effects combined lead to it causing the second largest depression of the phase transition peak height.  
Conversely DASB causes an intermediate shift in the potential of the first phase transition peak, but 
like Spiperone causes a larger increase in the capacitance of the monolayer. These two effects 
combined lead it to causing a large depression of the first phase transition peak height.  
Raclopride causes the lowest phase transition peak height depression, this is due to it not inserting into 
the monolayer to a great degree as is seen as a low increase in monolayer capacitance and it only 
binding to the head group intermediately, as seen as an intermediate peak potential shift.  
The height of the first phase transition peak after Rolipram addition is 50% of the original height. It 
causes a negligible change in the potential of this peak (-5.0 mV but with a large error of 6.6 mV), the 
interaction with the head group region therefore has little contribution to the disorder of the 
monolayer. The main contribution is therefore due to the drug molecule residing in the tail region of 
the monolayer, this is confirmed with an increase in monolayer capacitance of 0.89 µF cm-2.  
Only a very small proportion of Flumazenil inserts into the DOPC monolayer causing a very small 
increase in the monolayer capacitance. It interacts with the head group region of the phospholipid 
causing an intermediate shift of 95.8 mV in the potential of the first phase transition peak. These two 
distorting effects lead to an intermediate value for the phase transition peak height depression.  
The two drugs WAY and Fallypride do not follow this reasoning. Fallypride causes a significant 
increase in the monolayer capacitance and a shift in the potential of the first phase transition peak, 
however, it only causes a smaller peak height depression than the majority of the drugs. WAY, on the 
other hand, does not cause a significant increase in the monolayer capacitance or a significant 
potential shift but causes a significant depression of the height if the first phase transition peak.  
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10.5 Chapter Summary 
 
A model system was used to study the interaction of five Spiperone analogues and eight well 
characterised CNS drugs with a DOPC monolayer. The character of the interaction was interrogated 
using electrochemical techniques sensitive to the organisational state of the lipid monolayer.  
In the case of the Spiperone analogues, the largest disruptive effect toward the DOPC monolayer was 
observed for the larger CADs. The depression of the first phase transition peak was proportional to the 
molecular weight of the compound. The larger drugs also caused a larger increase in the capacitance 
of the DOPC monolayer, which implies they aggregate more in the tail region of the monolayer. 
Again, this increase was proportional to the molecular weight of the drug. The interaction of the drugs 
with the head group region was measured as a shift in the potential of the first phase transition peak. It 
was found that the intermediate sized analogues interacted more with the head group than the two 
extreme sized analogues.   
The largest disruptive interaction was observed for Spiperone out of the eight CNS drugs. It caused 
the largest shift in the potential of the first phase transition peak, caused the largest increase in the 
monolayer capacitance and caused the largest depression of the first phase transition peak.   
Previous studies82 have shown that the in vivo non-specific binding values of the CNS drugs studied 
here correlates with the in silico interaction energy with a DOPC molecule. The depression of the first 
phase transition peak and the increase in monolayer capacitance has a large correlation with this in 
vivo non-specific binding and the in silico interaction energy of the eight CNS drugs. This supports 
the idea that the non-specific binding measured in PET imaging of a drug or radiotracer is due to it 
interacting with lipids and aggregating in cell membranes.   
This technique could therefore be used to screen candidate drugs and radioligands to predict their non-
specific binding values (discussed in section 5.2.4). An assay that can select compounds that display 
the greatest likelihood of success would be extremely valuable due to the high cost and low-
throughput nature of PET imaging. 
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11 Conclusions 
 
The DOPC:LPC:OA composition diagram produced has revealed the presence of many swollen 
inverse bicontinuous cubic phases and combinations of these phases with the Lα and HII phase that 
have not been seen before in this system. These swollen cubic phases have large d-spacings not 
previously observed at atmospheric pressures in lipid systems. The trends in d-spacings and phase 
sequences observed by systematically altering the composition are explained by considering 
membrane curvature, the packing stress of amphiphiles and the fluidity of the membrane.  
A series of Spiperone analogues were successfully synthesised. Lipophilicity measurements showed 
that the analogues with a longer central carbon chain have a larger interaction with an immobilised 
artificial membrane (IAM) and the analogue SpipC0me which has no central carbon chain had a 
significantly smaller interaction. It was also shown that analogues with a longer central carbon chain 
had a larger interaction with DOPC unilamellar vesicles measured as an increase in Calcein leakage 
from the vesicles. These results imply that the CADs interaction with the lipid is dominated by a 
hydrophobic interaction between the lipid chains and the carbon chain in the CAD molecule. 
The interaction between the Spiperone analogues and multi lamellar vesicles (MLVs) was also 
investigated using SAXS and HPLC. In SAXS experiments, the CAD SpipC2me was shown to cause 
the largest bilayer repulsion, implying that it sits near the headgroup region of the lipid layer. In 
HPLC experiments SpipC2me was also shown to hydrolyse DOPC.  
A model system was used to study the interaction of five Spiperone analogues and eight well 
characterised CNS drugs with a DOPC monolayer. The character of the interaction was interrogated 
using electrochemical techniques sensitive to the organisational state of the lipid monolayer. In the 
case of the Spiperone analogues, the largest disruptive effect toward the DOPC monolayer was 
observed for the larger CADs. The depression of the first phase transition peak was proportional to the 
molecular weight of the compound. The larger drugs also caused a larger increase in the capacitance 
of the DOPC monolayer, which implies that aggregation in the tail region of the monolayer is 
influenced by the size of the central carbon chain in these molecules. Again, this increase was 
proportional to the molecular weight of the drug. The interaction of the drugs with the head group 
region was measured as a shift in the potential of the first phase transition peak. It was found that the 
intermediate sized analogues had a larger interaction with the head group than the two extreme sized 
analogues and SpipC2me caused the largest potential shift. This confirms what was found in the 
SAXS measurements that SpipC2me must sit near the headgroup region of the lipid layer.  
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The electrochemical measurements showed that Spiperone has the largest disruptive interaction with 
the DOPC monolayer out of the eight CNS drugs. It caused the largest increase in the monolayer 
capacitance which implies that more of it aggregates in the tail region of the monolayer than any of 
the other CNS drugs tested. It also caused the largest shift in the potential of the first phase transition 
peak and has been shown to hydrolyse DOPC bilayers and cause bilayer swelling in previous 
studies169. These results combined suggest that like SpipC2me, Spiperone sits near the headgroup 
region of the lipid layer.  The interaction of Spiperone with the DOPC monolayer was much larger 
than for any of the Spiperone analogues synthesised, this suggests that the 1-phenyl-1,3,8-triazaspiro-
[4,5]-decan-4-one part of the molecule (shown in figure 6.1.2) has a smaller influence on Spiperones 
interaction with lipids, as this is a common feature of Spiperone and the Spiperone analogues, than the 
fluorophenyl group, which is unique to Spiperone.  
The depression of the first phase transition peak and the increase in monolayer capacitance in the 
forward scan has a large correlation with the in vivo non-specific binding and the in silico interaction 
energy of the CNS drugs measured previously89. This supports the idea that the non-specific binding 
of a drug or radiotracer measured in PET imaging is due to it interacting with lipids and aggregating 
in cell membranes.  This technique could therefore be used to screen candidate drugs and radioligands 
to predict their non-specific binding values. An assay that can select compounds that display the 
greatest likelihood of success would be extremely valuable due to the high cost and low-throughput 
nature of PET imaging. 
These results have provided a means to gain further insight into the interaction of drug molecules with 
lipid membranes at a molecular level. 
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13 Appendix 
 
13.1 NMR and LCMS Data 
 
(i) SpipC0me NMR 
(ii – iv) SpipC0me LCMS 
(v) SpipC2me NMR 
(vi-viii) SpipC2me LCMS 
(iv) SpipC3mr NMR 
(x – xii) SpipC3me LCMS 
(xiii) SpipC4me NMR 
(xiv – xvi) SpipC4me LCMS 
(xvii) SpipC6me NMR 
(xviii – xx) SpipC6me LCMS 
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